ISSN 0221-8747

Metabolic Bone Disease

& Related Research

Cumulative Subject and Author Index Volumes 1-4, 1978-1983

Co-Publishers

PERGAMON PRESS

New York / Oxford / Toronto / Paris / Frankfurt / Sydney

S.N.P.M.D.

Paris

(677)

Metabolic Bone Disease

& Related Research

Co-published by
Pergamon Press and SNPMD

Editors

- Ralph S. GOLDSMITH, San Francisco (USA)
- Pierre J. MEUNIER, Lyon (France)

Managing Editors

- Roland BARON, New Haven (USA)
- David B.P. GOODMAN, Philadelphia (USA)

Editorial Board

- Constantine ANAST, Cambridge (USA)
- Clarke ANDERSON, Lawrence (USA)
- Claude ARNAUD, San Francisco (USA)
- Sonia BALSAN, Paris (France)
- David J. BAYLINK, Washington (USA)
- Olav L.M. BIJVOET, Leiden (Netherlands)
- Itzhak BINDERMAN, Tel-Aviv (Israel)
- Alan BOYDE, London (England)
- Arnold S. BRICKMAN, Sepulveda (USA)
- Gunther DELLING, Hamburg (FR Germany)
- Hector F. DE LUCA, Madison (USA)
- H.E. DE WARDENER, London (England)
- Jan A. FISCHER, Zurich, (Switzerland)
- Herbert FLEISCH, Bern (Switzerland)
- Harold M. FROST, Pueblo, (USA)
- Francis H. GLORIEUX, Montreal (Canada)
- John G. HADDAD, Philadelphia (USA)
- Brian K. HALL, Halifax (Canada)
- Robert P. HEANEY, Omaha (USA)
- Marijke E. HOLTROP, Boston (USA)
- Webster S.S. JEE, Salt Lake City (USA)
- G.F. JOPLIN, London (England)
- Arnold J. KAHN, Saint Louis (USA)
- John KANIS, Sheffield (England)
- Stephen M. KRANE, Boston (USA)
- Joseph LANE, New York (USA)
- Iain MAC INTYRE, London (England)
- James L. MATTHEWS, Dallas (USA)
- Sandy C. MARKS, Worcester (USA)
- Flemming MELSEN, Aarhus (Denmark)
- Cedric MINKIN, Los Angeles (USA)
- Gregory R. MUNDY, San Antonio (USA)
- Anthony W. NORMAN, Riverside (USA)
- Michael E. NORMAN, Philadelphia (USA)
- Maureen OWEN, Oxford (England)
- A. Michael PARFITT, Detroit (USA)
- William A. PECK, Saint Louis (USA)
- Solomon POSEN, Sydney (Australia)
- Lawrence G. RAISZ, Farmington (USA)
- Howard RASMUSSEN, New Haven (USA)
- Eberhard RITZ, Heidelberg (FR Germany)
- Graham RUSSELL, Sheffield (England)
- Robert SCHENK, Bern (Switzerland)
- David J. SIMMONS, Saint Louis (USA)
- Tatsuo SUDA, Tokyo (Japan)
- Steven L. TEITELBAUM, Saint Louis (USA)
- Roy E. WUTHIER, Columbia (USA)

Aims and Scope

METABOLIC BONE DISEASE & RELATED RESEARCH provides an interdisciplinary forum for the rapid publication of original experimental or clinical studies and review articles dealing with both normal and pathological processes which occur in bone or which occur in otner tissues affecting bone metabolism. Additionally, well studied case reports are invited.

Areas of specific interest are:

BONE: Cellular basis of normal and disordered bone development and remodeling. Histology, static and dynamic histomorphometry at the light and electron microscopic levels.

—Organ and cell culture systems as *in vitro* models for studies of bone and bone disease.
—Response of normal and diseased bone to trauma and stress.
—Response of bone to therapeutic agents.
—Physical studies of calcium and bone.
—Radiology of bone.
—The metabolism of bone matrix and mineral.
—Mechanisms of normal and disordered calcification.
—Studies of non-mammaliam calcifying systems with a clear relevance to normal or pathologic processes in human bone.

ENDOCRINE: Biochemistry and physiology of Parathyroid hormone, Vitamin D metabolites, Calcitonin, Prostaglandins and other hormones (Thyroid Hormones, Estrogens, Glucocorticoids, Growth Hormone . . .) affecting bone.

KIDNEY: Renal biochemistry and physiology related to calcium, phosphorus and bone metabolism. Mineral homeostasis, renal osteodystrophy, chronic acid/base disorders, Vitamin D metabolism and action.

GASTROINTESTINAL TRACT: Biochemistry and physiology of normal and disordered mineral absorption, Vitamin D action and metabolism.

Particular attention will be placed on the continuum between experimental studies and clinical applications.

Manuscripts should be addressed to the Managing Editors:

Roland BARON and David B.P. GOODMAN
Department of Medicine, Endocrine Section
Yale University School of Medicine
333 Cedar Street
New Haven, Connecticut 06510, USA
Tel: (203) 432-4908

Publishing, Subscription and Advertising Offices: Pergamon Press, Inc., Fairview Park, Elmsford, NY 10523, USA; or Pergamon Press Ltd., Headington Hill Hall, Oxford OX3, 0BW, England.

Published bi-monthly. *Annual subscription rate* (1984): US $250.00 for libraries and other multiple-reader institutions; *Two-year rate* (1984/85): US $475.00. Special reduced rate for individuals whose library subscribes at regular rate (1984): US $140.00. Special rate for members of the *American Society for Bone and Mineral Research*, *European Calcified Tissue Society*, and *Bone and Tooth Society of Great Britain*, (1983): US $90.00. Prices include insurance and surface postage; air mail subscriptions extra. For information on back volumes and microform subscriptions, contact your nearest Pergamon Press office.

Copyright © 1983 Pergamon Press Ltd. Printed in the USA.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher, if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the U.S.A.: The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

The Item-Fee Code for this publication is: 0221-8747/83 $3.00 + .00

Metab. Bone Dis. & Rel. Res. 4, iii-xiv (1983)
Printed in the USA. All rights reserved.

0221-8747/83 $3.00/0
Copyright © 1983 Pergamon Press Ltd.

Metabolic Bone Disease & Related Research

Cumulative Subject Index Volumes 1-4, 1978-1983

Absorption, see Calcium absorption
Acid groups (mineralization nodules) *4*:77, *4*:77, *4*:79, *4*:80, *4*:82, *4*:83
Acid phosphatse *3*:101, *3*:259
Acid phosphatase activity (matrix vesicles)
  bone *3*:210, *3*:211, *3*:212, *3*:213, *3*:214
  extracelluar *1*:186, *1*:189
  osteosarcoma *1*:227, *1*:229, *1*:232
Acitinide uptake (in vitro) *2*:281, *2*:282, *2*:283
ACP. see Amorphous calcium phosphate
Actin *1*:227, *1*:232
Actinomyces naeslundii *1*:145, *1*:146
Adenosine monophosphate. See Cyclic AMP
Adenosine triphosphate (ATPase)
  ACP *2*:7, *2*:8
  articular cartilage *1*:115, *1*:116, *1*:118
  matrix vesicle calcification *1*:169, *1*:170, *1*:171
  matrix vesicles (bone) *3*:210, *3*:212, *3*:213
  PEP-induced efflux *1*:175, *1*:176
Adenosine triphosphate (ATPase) activity
  extracellular matrix vesicles *1*:186, *1*:188, *1*:189, *1*:190
  osteosarcoma matrix vesicles *1*:229, *1*:232
Adenylate cyclase activation (PTH metabolism) *2*:25, *2*:26, *2*:27, *2*:28, *2*:29, *2*:30
Adrenal cortex hypertrophy *4*:121, *4*:122, *4*:126
Adult hereditary bone dysplasia. see Hereditary bone dysplasia (adult)
Affinity chromatography *3*:43, *3*:44, *3*:45
Age (calcium transport) *1*:30, *1*:31, *1*:32
Aging (bone) *1*:36, *1*:38, *3*:6
Algodystrophy *4*:305, *4*:306, *4*:309
Alkaline phosphatase (APase)
  anticonvulsant therapy *4*:44, *4*:45, *4*:46
  cartilage (articular) *1*:115, *1*:116, *1*:118
  cartilage (epiphyseal) *1*:161, *1*:162, *1*:163, *1*:164, *1*:166, *1*167
  cartilage fractions *1*:125, *1*:126, *1*:127, *1*:128
  Cl_2MDB-treated rats *2*:41, *2*:43, *2*:47
  CT-EHDP therapy *1*:251, *1*:253, *1*:254 *1*:258, *1*:259
  HCT therapy *2*:87, *2*:88
  matrix mineralization *1*:65, *1*:67, *2*:53, *2*:60
  NCBP activity *4*158, *4*:159, *4*:160
  tissue mineralization *1*:179
  24,25-$(OH)_2D_3$ therapy *2*:12, *2*:14
Alkaline phosphatase (APase) activity
  calcification *3*:62, *3*:63, *3*:65
  matrix vesicles (bone) *3*:210, *3*:211, *3*:212, *3*:214
  matrix vesicles (extracellular) *1*:186, *1*:189, *1*:190
  matrix vesicles (osteosarcoma) *1*:227, *1*:229, *1*:232
Alkaline phosphatase (APase) (cartilage) *3*:67, *3*:68, *3*:74, *3*:75
Alkaline phosphatase (APase) inhibitors *3*:61, *3*:62, *3*:63, *3*:64, *3*:65
Alkaline phosphatase (Paget's disease) *3*:219, *2*:221, *3*:301, *3*:302, *3*:303, *3*:304, *3*:305
  biochemical marker *3*:255, *3*:256, *3*:257
  EHDP therapy *3*:321
Alkaline phosphatase (plasma)
  bone turnover (uremia) *4*:197, *4*:298, *4*:300, *4*:301, *4*:302
  DPH-treated rats *4*:273, *4*:274
  PHP (uremia) *4*:298, *4*:299, *4*:300
  SV-treated rats *4*:273, *4*:274
  1α $(OH)D_3$ *1*:17, *1*:18
Alkaline phosphatse (serum) (SAP)
  Cl_2MDP therapy *4*:325, *4*:326, *4*:327
  EHDP therapy *3*:301, *3*:302
  HCT therapy *2*:87, *2*:88
Alkaline phosphatase (APase) ultrastructure *4*:353, *4*:354, *4*:360
Alkaline phosphatases (chondrocytes/matrix vesicles)
  purification *1*:161, *1*:162, *1*:163, *1*:166, *1*:167
  subunit structure *1*:164, *1*:165, *1*:166, *1*:167
Alpha-fetoprotein (plasma) (AFP) *3*:91, *3*:92, *3*:95, *3*:96
Aluminum (serum)
  dialysis osteodystrophy *3*:177, *3*:178
  renal failure *4*:370
Alveolar bone. see Bone (alveolar)
Amino acids. See Urinary amino acids
Aminoaciduria *2*:86
Amino hydroxypropylidene diphosphonate (APD)
  hypercalcemia *4*:368
  Paget's disease *3*:217, *3*:224, *3*:227, *3*:228
Amorphous calcium phosphate (ACP)
  apatite formation *2*:7, *2*:8
  ATPase *1*:180, *1*:181
  hyroxyapatite formation *1*:182
  SCT action *2*:119, *2*:120
Analgesics (Paget's disease) *3*:222
Anticonvulsant drugs (osteomalacia) *4*:370
Anticonvulsant drugs (rats)
  bone growth *4*:269, *4*:270, *4*:271, *4*:272, *4*:273, *4*:274
  plasma calcium *4*:273, *4*:274
  vitamin D depletion *4*:269
Anticonvulsant osteomalacia *1*:45, *1*:46, *1*:47, *2*:83, *2*:85, *4*:269, *4*:274
Anticonvulsant therapy
  biochemical values *2*:79, *4*:44, *4*:45, *4*:46
  bone resorption *2*:185
  bone status (children) *4*:43, *4*:44, *4*:45, *4*:46
  calcification rate *4*:181, *4*:183
  calcium homeostasis *3*:17
  osteoid dynamics *2*:77, *2*:80, *2*:81
  trabecular bone remodeling *2*:77, *2*:79, *2*:80
  trabecular bone remodeling site *4*:181, *4*:183, *4*:184
  vitamin D deficiency *2*:81
  vitamin D metabolism *3*:17, *3*:18, *3*:20, *3*:21
Antihypercalcemia agents *2*:185
Anti-inflammatory drugs (nonsteroidal) *2*:185
Antimeasles antibodies *3*:236
AO (avian osteopetrosis). see Osteopetrosis (avian)
APase. see Alkaline phosphatase
Apatite. see also Hydroxyapatite *1*:83, *1*:97, *1*:102
  bone *2*:3
  crystal growth *2*:4, *2*:5, *2*:7
Apatite clusters *1*:110
Apatite crystallization inhibition *4*:157, *4*:159, *4*:160, *4*:161
Apatite crystals (cartilage mineralization) *1*:109, *1*:110, *1*:112
Apatite formation *4*:157
  ACP *2*:7, *2*:8
  phosphorylated bone protein *4*:161
  proteolipid *1*:144
Apatitic mineral formation *1*:125
APD. see Amino hydroxpropylidene diphosphonate
Apoprotein *1*:144
Arachidonic acid metabolism products
  bone metastases *2*:169, *2*:170
  bone resorption *2*:167, *2*:168, *2*:169
  hypercalcemia *2*:170
Arthroplasty
  Paget's disease *3*:275, *3*:276
  total hip *3*:337, *3*:338, *3*:339, *3*:340, *3*:341
Articular cartilage. see Cartilage (articular)
Avian osteopetrosis. see Osteopetrosis (avian)

Bacterionema matruchotii model (biologic calcification) *1*:143, *1*:144, *1*:145, *1*:146
Barium levels (pagetic bone) *4*:243, *4*:244, *4*:245
Basic multicellular units (BMU) (bone remodeling) *4*:284, *4*:285, *4*:286, *4*:287
Beta-glycerophosphate (BGP). see also osteocalcin *1*:195, *1*:196
Bicarbonate (serum) (25-$(OH)D_3$ — 1,25-$(OH)_2D$) *4*:256, *4*:258
Bisphosphonates. see Diphosphonates
BMC. see Bone mineral content
BMU. see Basic multicellular units
Bone accretion rate studies *3*:27, *3*:29
Bone (alveolar)
  healing *1*:185, *1*:191
  mineral deposits *1*:119, *1*:120, *1*:123
  osteoblasts *1*:119, *1*:120, *1*:123
  resorption *3*:107, *3*:110, *3*:111, *3*:114
Bone apposition *1*:306, *1*:308
Bone apposition rates *1*:274
Bone architecture. see Bone modeling
Bone blood flow
  bone scan interpretation *3*:269
  cortex and marrow (canine) *2*:123, *2*:124, *2*:125, *2*:126, *2*:127, *1*:128
  microsphere technique *4*:313, *4*:314, *4*:315, *4*:316, *4*:317

Bone Blood Flow (cont.)
NTON 4:313, 4:314, 4:315, 4:316
Paget's disease 3:263, 3:267
skeletal 3:263, 3:267, 3:268
Bone (calcium transport) 2:143, 2:144, 2:146, 2:148, 2:149
Bone cartilage (PHA-P administration) 4:196, 4:197
Bone cell differentiation 1:74, 1:75, 1:79
Bone cell kinetics (growth cartilage) 3:191, 3:192, 3:193, 3:196
Bone cell receptor activity 2:179, 2:180
Bone cells
calvarial 1:74, 1:75, 1:79
cultivation 4:367
matrix vesicle production 1:231
Bone (cortical)
mineralization 3:159, 3:160, 3:162, 3:163
parameters 3:35
remodeling 3:162, 3:163, 4:353, 4:354, 4:355, 4:356, 4:357, 4:358
spatial structure 4:369
turnover 3:63
Bone coupling. see also Bone formation; Bone resorption
aging 1:36, 1:38, 3:6
endosteal bone 2:131
mechanism 2:131, 2:132
osteoporosis (pathogenesis) 4:1, 4:5
osteoporosis (postmenopausal) 3:3, 3:4, 3:5, 3:6
Paget's disease 3:5, 3:260
PTE stimulation 2:132, 2:133, 2:134
PTH stimulation 2:131, 2:132
quantum concept 4:1, 4:2, 4:3, 4:4, 4:5
Bone coupling factor 3:5
Bone culture (PTH) 1:67
Bone curvatures (long) 4:224, 4:225
Bone density
computed tomography (osteoporosis) 4:169, 4:170, 4:171, 4:172
densitometry 1:43, 1:44, 4:363
EHDP-treated dog 3:295, 3:296
iliac crest 3:187, 3:188, 3:189
Bone destruction mechanism 2:174
Bone dysplasias. see also Hereditary bone dysplasia 3:228
Bone elongation 3:191, 3:195, 3:196
Bone (endosteal)
coupling 2:131
formation 1:269, 1:272, 1:274, 1:275
marrow 2:240
resorption 2:223, 2:224, 2:225, 2:229, 2:272, 2:273, 2:274
surfaces 1:79
vasculature 2:245
Bone fluoride concentration (osteoporosis therapy) 4:31, 4:32, 4:33, 4:34, 4:35, 4:36
Bone formation 1:75, 2:110, 3:323
active bone forming surface 4:237, 4:238, 4:239, 4:240
calcium repletion 1:269, 1:271, 1:272, 1:273, 1:275
Cl_2MDP (rats) 2:39, 2:40, 2:42, 2:43, 2:46, 2:47
cortisone acetate (mice) 3:199, 3:200, 3:201, 3:204, 3:205, 3:206
EHDP (dogs) 3:291
EHDP (rats) 2:39, 2:40, 2:41, 2:43
endosteal 1:269, 1:271, 1:272, 1:74, 1:275
fluorosis 1:52
hyper-/hypothyroidism 3:181, 3:182, 3:183, 3:184
in vitro 2:131, 2:132
matrix vesicles 1:185
Bone formation (cont.)
osteosarcoma 1:228, 1:229
pycnodysostosis 2:99, 2:101, 2:103, 2:104, 2:105
ROD 3:175, 3:177, 3:178
vitamin D 1:8
vitamin D derivatives 1:23, 1:24, 1:27
weightlessness 4:350, 4:351
Bone formation index (APase) 3:301
Bone formation rate
Paget's disease 3:255, 3:261
pathological conditions 1:45, 1:46, 1:47
Bone formation-bone resorption. see also Bone coupling; Bone formation; Bone resorption 3:3, 3:4, 3:5, 3:6, 3:257, 3:260
balance 4:1, 4:2, 4:3, 4:4, 4:285
Bone (growing) (Calcium oxalte monohydrate deposition) 4:49, 4:50, 4:51, 4:53, 4:55, 4:58
Bone growth
anticonvulsant therapy (rats) 4:269, 4:270, 4:271, 4:272, 4:273, 4:274
bone modeling 4:226
cortical thickness 4:224
diameter 4:223, 4:224
paralyzed vs. normal limb 4:225
Rod (juvenile) 4:255
skeletal IO 4:283
TPTX rats 4:270, 4:271, 4:272, 4:274
weightlessness (rats) 4:69, 4:71, 4:73, 4:347, 4:349, 4:351
Bone healing
matrix vesicles 1:189
mithramycin therapy (breast cancer) 2:200, 2:201, 2:202
Bone histology
Paget's disease 3:310, 3:311, 3:312
osteomalacia 2:85
osteomalacia (anticonvulsant) 2:83
Bone histomorphometry
active bone-forming surface 4:237, 4:238, 4:240, 4:241
anticonvulsant therapy 2:79
corticosteroid-treated patients 1:304, 1:305
Cushing's syndrome 1:303, 1:304, 1:305
dialysed patients 3:175, 3:176, 3:177, 3:178
EHDP (dogs) 3:291, 3:292, 3:293, 3:295
femoral neck fractures 4:87, 4:88, 4:89, 4:90
iliac crest 4:231, 4:232, 4:233, 4:234, 4:235
jejuno-ileal bypass 2:79
MCT 4:17, 4:18, 4:19, 4:20, 4:22
osteomalacia (anticonvulsant) 2:83
osteomalacia (diagnosis) 2:85
osteomalacia (hypophosphatemic vitamin D-resistant) 4:249, 4:250, 4:251
osteoporosis 1:35, 1:303, 1:305, 3:23, 3:27, 3:29
pycnodysostosis 2:99, 2:101, 2:103, 2:204
steroid effect reversibility 1:306, 1:307, 1:310
trabecular bone 4:291, 4:292
uremic bone disease 1:39, 1:40, 1:41, 1:43
VDRR 3:32, 3:35, 3:160
Bone immobilization. see also Bone repletion 2:262
Bone labels 4:237, 4:238, 4:239, 4:240
Bone (lamellar) 1:49, 1:50, 1:325, 1:326, 1:327, 1327, 1:329, 1:330, 1:331, 1:333
Bone lesions
cadmium chloride exposure 2:247, 2:248, 2:250
pageloid 3:253
Paget's disease 4:103, 4:106, 4:109
SCT therapy (MM) 4:41, 4:42
Sudek's atrophy 4:305, 4:308, 4:309, 4:310
Bone lipids metabolism (corticosteroid therapy) 4:319, 4:320, 4:321, 4:322
Bone loss
postmenopause 4:178
simulated weightlessness 4:347, 4:349, 4:350, 4:351
Bone marrow
blood flow 2:123, 2:124, 2:125
endosteal bone 2:240
fat 4:69, 4:71, 4:347, 4:349, 4:350, 4:351
infusion (osteopetrosis) 3:91, 3:92, 3:97, 3:107, 3:108, 3:131, 3:132
lipid content 4:321, 4:322
microvascular bed 2:239, 2:240, 2:241, 2:242, 2:245, 2:246
osteopetrosis (infantile malignant) 3:140
transplants 2:36, 3:78, 3:79
vasculature 2:240, 2:245, 3:239
Bone mass
EHDP-treated rats 4:121, 4:122, 4:123, 4:125
PHA-P administration 4:194, 4:197
crystal growth 2:5
development *in vitro* 2:71
mineralization 4:77, 4:78, 4:82, 4:83
Bone matrix proteins (noncollagenous) (NCBP)
apatite-extracted 4:158, 4:159, 4:160
Gla-containing 4:157, 4:159, 4:160
Bone maturation (chronic uremia) 3:191, 3:196
Bone metabolism
in vitro 2:131, 2:132, 2:133, 2:134
rhythms 2:61
Bone (metaphyseal) 2:52, 4:222
Bone metastases
arachidonic acid metabolism 2:169, 2:170
hypercalcemia (malignant) 2:173, 2:174, 2:175
Bone mineral content (BMC)
anticonvulsant therapy 3:18, 4:43, 4:44, 4:45, 4:46
osteoporosis 4:169, 4:172
parathyroidectomy 2:257, 2:258, 2:259, 4:169, 4:172, 4:189, 4:190
Bone mineral crystallinity (osteopetrotic rats) 2:33, 2:34, 2:35, 2:36
Bone mineral determination (uremic bone disease) 1:40, 1:43
Bone mineral release 1:78, 1:79
Bone mineral structure 1:105, 1:107
Bone mineralization
APase activity 3:61, 3:63, 3:65
corticosteriod therapy 4:322
pyrophosphate inhibition 3:280
rate (ROD) 3:175, 3:177, 3:178
theories 1:179, 1:18
vitamin D 1:7, 1:9
1,25-$(OH)_2D_3$ 1:12
Bone mineral-organic complexes 2:119, 2:120
Bone modeling
architectural error 4:218, 4:219, 4:220
barriers 4:226
drifts 4:217, 4:218
flexural algorithm 4:220, 4:221, 4:222, 4:223, 4:224, 4:225, 4:226
genetic and mechanical factors 4:227, 4:228
integrating mechanism 4:226
PTH 2:257, 2:259, 2:260
stress/strain 4:218, 4:219, 4:221, 4:224, 4:225
Bone modeling (children) 4:225, 4:226
Bone modifications (Sudek's atrophy) 4:306, 4:307, 4:308
Bone morphometry (inter-/intraindividual differences) 3:187, 3:188, 3:189
Bone (necrotic) 4:151, 4:152, 4:153, 4:154, 4:155
Bone (osteopetrotic) 2:36, 3:123
Bone (pageloid) 3:253, 4:243, 4:244, 4:245, 4:246

Bone pain
analgesics (Paget's disease) 3:222
Cl_2MDP (MM) 4:164, 4:166, 4:167
CT (Paget's disease) 3:269
EHDP (Paget's disease) 3:302
mithramycin (Paget's disease) 3:343, 3:345
Bone parameters (PTE-treated TPTX rats) 1:313, 1:314
Bone pericellular sites 2:113, 2:118, 2:119, 2:120
Bone remodeling
anticonvulsant therapy 2:77, 2:79, 2:80
BMU 4:284, 4:285, 4:286, 4:287
cadmium chloride interference 2:250
Ca-PL-PO_4 complexes 4:151, 4:153, 4:154, 4:155
EHDP-treated dogs 3:289, 3:292, 3:293, 3:296
hypercalcemia 1:279, 1:281, 1:286, 1:287
jejuno-ileal bypass 2:77, 2:79, 2:80
osteoporosis 2:107, 2:108, 2:109, 2:110
Paget's disease 1:251, 3:243, 3:304
skeletal IO 4:283, 4:284
skeletal sarcoidosis 3:171, 3:173
VDRR 3:35, 3:36

Bone remodeling site
cortical 4:353, 4:354, 4:355, 4:356, 4:357, 4:358
MWT 4:181, 4:182, 4:184
true wall thickness 4:113, 4:114, 4:115, 4:116, 4:117, 4:118
Bone repletion
immobilization 1:269, 1:270, 1:271, 2:272, 2:273, 2:274, 2:275
osteoclast reduction 4:201, 4:203, 4:205, 4:206, 4:207
osteoclasts 1:274, 1:275
PTH 1:275
Bone resorption
alveolar bone 3:107, 3:110, 3:111, 3:114
anticonvulsant therapy 2:185
arachidonic acid metabolism 2:167, 2:168, 2:169
biochemical basis 2:178, 2:179
calvarial cell culture 1:78
Cl_2MDP-treated rats 2:39, 2:41, 2:43, 2:46, 2:47
corticosteriod treatment 1:305, 1:306, 1:308
dialysis ROD 3:175, 3:177, 3:178
diphosphonates 2:261, 2:263, 2:265
EHDP-treated dogs 3:290, 3:291, 3:292, 3:296
EHDP-treated rats 2:39, 2:41, 2:43, 2:46, 2:47
endosteal bone 1:272, 1:273, 1:274, 2:223, 2:224, 2:225, 2:229
enzymes 2:179
flurosis 1:152, 1:153
hypercalcemia 1:280, 1:281, 1:282, 1:286, 2:152, 2:155
hyperthyroidism 3:181, 3:182, 3:183, 3:184
hypothyroidism 3:181, 3:182, 3:183, 3:184
intracortical 2:223, 2:224, 2:225, 2:226, 2:227, 2:228, 2:229, 2:230
lacunae 4:371
osteoclastic 1:67, 2:178, 2:179
osteopetrosis 4:265, 4:267
osteopetrosis (congenital malignant) 3:143, 3:144, 3:145, 3:146
osteopetrosis (infantile) 3:135, 3:136, 3:139
osteoporosis (postmenopausal) 2:107, 2:108
Paget's disease 3:219, 3:221, 3:260, 3:305
prostaglandins 2:167, 2:168, 2:169, 2:181
PTH 2:279, 4:367, 4:368
pycnodysostosis 2:100, 2:101, 2:203, 2:104
pyrophosphate 3:280
regulation 2:180, 2:181, 2:182

Bone resorption (cont.)
ROD 2:223, 2:224, 2:225, 2:226, 2:227, 2:228, 2:229, 2:230
vitamin D derivatives 1:23, 1:27, 1:28
vitamin D metabolites 1:8
uremia 4:297, 4:298, 4:299, 4:300, 4:301, 4:302
1,25-$(OH)_2D_3$ therapy 2:223, 2:224, 2:225, 2:226, 2:227, 2:228, 2:229
24, 25-$(OH)_2D$ (plasma) 4:25, 4:26, 4:27, 4:28, 4:29
Bone resorption activation 2:181, 2:182
Bone resorption defect
osteopetrosis (malignant congenital) 3:101
osteopetrotic rats 3:117, 3:118, 3:119, 3:120
Bone resorption index 3:301
Bone resorption inhibition 2:178, 2:182, 2:183, 3:261
anticonvulsants 2:185
anti-inflammatory drugs (nonsteriodal) 2:185
colchicine 2;184
diphosphonate 3:281, 3:282
EHDP therapy 3:312, 3:313
mithramycin 2:184, 2:185
Paget's disease treatment 3:255
Bone resorption (uremia) 4:297, 4:298, 4:299, 4:300, 4:301
Bone scans
bone blood flow 3:269
clinical use 3:253
Paget's disease 3:240, 3:243, 3:248, 3:253
radiology 3:244
skeletal metabolic activity 3:243, 3:249, 3:250, 3:253
Bone scintigraphy (Paget's disease) 4:104, 4:105, 4:106, 4:107, 4:108, 4:109
Bone (sclerotic) 4:152, 4:153, 4:154, 4:155
Bone surface
electrical phenomena 4:226
endosteal bone 1:79
quiescent 1:282, 1:283, 1:284
Bone surface-cell barrier 2:245
Bone (trabecular). see Trabecular bone
Bone tumor cell chemotaxis 2:174, 1:175
Bone tumor detection 4:362
Bone turnover
Cl_2MDP 4:327
CT therapy 3:319, 3:320
diphosphonate 4:327
hip fractures 4:85, 4:90
hydroxyproline (plasma) 4:297, 4:298, 4:299, 4:300
hypercalcemia 1:279, 1:280, 1:281, 1:282
osteoporosis 3:23, 3:24, 3:25, 3:26, 3:27, 3:29, 4:2, 4:3
Paget's disease 3:255, 3:256, 3:257, 3:260
skeletal sarcoidosis 3:171, 3:173
uremia 4:297, 4:298, 4:300, 4:301, 4:302
1α-$(OH)D_3$ 4:297, 4:299, 4:301
Bone volume (osteoporosis) 2:107, 2:109, 2:110
Bone-blood equilibrium (calcium homeostasis) 1:279, 1:282, 1:283, 1:284, 1:285, 1:286
Bone-forming surface (active) 4:237, 4:238, 4:240, 4:241
Bone-lining cells 2:239, 2:240, 2:241, 2:245, 2:246

Cadmium intoxication (chronic) 2:247, 2:248, 2:250
Calcifediol. see 25-Hydroxycholecalciferol; 25-Hydroxyvitamin D; 25-OHD_3
Calcification see also Mineralization 1:125, 1:155
actinide uptake 2:281, 2:282, 2:283
APase activity 3:61, 3:62, 3:63, 3:65, 4:60

Calcification (cont.)
aortic 1:213, 1:214, 1:215, 1:216
biologic (proteo-lipid dependent) 1:43, 1:44, 1:45, 1:46
Ca-PL-PO_4 complexes 4:151, 4:155
cartilage 1:179, 1:183
cortisone acetate effect 3:199, 3:200, 3:201, 3:204, 3:205
EHDP 3:40
epiphyseal growth plate 1:89, 1:90, 1:92
glucocorticoid 2:67, 2:76
growth plate cartilage 1:93, 1:95, 1:96
inhibition 1:213, 3:216
in vitro 2:65, 2:66, 2:71
in vivo (CSS) 1:40, 1:141
lipid-induced 1:137, 1:138, 1:139, 1:140, 1:141
lipoprotein 2:281, 2:282, 2:283
matrix vesicles 1:83, 1:85, 1:86, 1:89, 1:90, 1:92, 1:97, 1:202, 1:203, 4:129, 4:130
microbial model 1:143, 1:144, 1:145, 1:146
scorbutic cartilage 1:206, 2:207, 2:216
Calcification rate
anticonvulsant therapy 4:181, 4:183
corticosteriod-treated patients 1:306
EHDP therapy 3:309, 3:311, 3:313, 3:314
intra-observer observation 4:181, 4:183, 4:184
Calciphylaxis (ultrastructural) 1:219, 1:220, 1:221, 1:222, 1:223, 1:224, 1:225
Calcitonin (CT)
antibodies 3:223
blood levels (osteopetrosis) 3:151, 3:152, 3:153
bone cells 2:113
bone resorption inhibition 2:182, 2:183
calcium homeostasis 2:147
calcium (plasma) 2:93, 2:152
Ca-PL-PO_4 2:113, 2:118, 2:119, 2:120
hyper-/hypocalcemic effect 2:207, 2:208, 2:209, 2:113, 2:118, 1:120
secretion 4:361
serum CT 3:41
vitamin D therapy 4:25, 4:28, 4:29
Calcitonin (human) (HCT)
hypocalcemic/hypophosphatemic effects 2:93, 2:94, 2:95, 2:96
Paget's disease 2:87, 2:88, 2:89
Calcitonin (immunoreactive) (iCT)
HCT therapy 2:93, 2:95, 2:96
IH pathogenesis 3:39, 3:41
MCT 4:17, 4:18, 4:20, 4:21
oral phosphate therapy 3:40, 3:41
Calcitonin (salmon) (SCT) 4:364
ACP 2:119., 2:120, 4:22
adult hereditary bone dysplasia 3:11, 3:15
hypocalcemic/hypophosphatemic effect 2:93, 2:94, 2:95
MM 4:39, 4:40, 4:41
osteopetrosis (congenital malignant) 3:146
uremia 4:300, 4:301, 4:302
Calcitonin (CT) therapy
arthroplasty 3:275, 2:276
bone cell treatment 1:74
bone remodeling 4:22
bone turnover reduction 3:319, 3:320
hereditary bone dysplasia 3:15
hypercalcemia (malignant) 2:194, 2:195
hypercalcemia (severe) 2:207, 2:208, 2:209, 2:210, 2:211
indications 2:89, 2:90
low dose 2:96
MM 4:39, 4:40, 4:41, 4:42
osteoclasts 4:367
osteoporosis 2:107, 2:108
Paget's disease 3:19, 3:20, 3:222, 3:223,

Calcitonin (CT) therapy (cont.)
3:253, 3:267, 3:269, 3:307, 3:317, 3:319, 3:320, 3:332
renal failure 2:194, 2:195
uremia 4:297, 4:300, 4:301, 4:302
Calcitonin-EHDP therapy (Paget's disease) 1:251, 1:252, 1:253, 1:255, 1:257, 1:258, 1:259, 3:323, 3:324
Calcitriol. see 1α-25-$(OH)_2D_3$; 1,25-$(OH)_2D_3$
Calcium absorption
GH 2:251, 2:252, 2:253, 2:254
gut 2:147, 2:148, 2:155
hyperabsorption 1:288, 1:289
intestinal 1:23, 1:24, 1:27, 1:28
kidney 2:144, 2:148
malabsorption 3:165
measurement 2:233, 2:234, 2:236, 2:237
1,25-$(OH)_2D_3$ 2:11, 2:12, 2:13, 2:14
1,24,25-$(OH)_3D_3$ 1:295, 1:296, 1:297
24,25-$(OH)_2D_3$ 2:11, 2:12, 2:13, 2:14
Calcium accretion rate 4:121, 4:125, 4:126
Calcium analysis 1:155, 1:156, 1:157
Calcium balance 1:279, 1:295
^{45}Ca-^{47}Ca 2:233, 2:234, 2:236
CT therapy 3:323
CT-EHDP therapy 1:255, 1:258, 3:324
EHDP therapy 3:324
hyperthyroidism 1:280, 1:281, 1:282
phosphorylated bone protein 4:157, 4:161
PTH 2:145, 2:146
1,25-$(OH)_2D$ 2:144, 2:145
Calcium binding sites 1:120
Calcium concentration 1:100, 1:102, 1:185
Calcium deficiency 4:121, 4:122, 4:123, 4:125, 4:126
Calcium deposition 1:169
Calcium deprivation 4:201, 4:203, 4:205, 4:206, 4:207, 4:208
Calcium distribution 2:143
condylar cartilage 4:143, 4:144, 4:147, 4:149
growth plate 4:135, 4:138
Calcium efflux 3:118
mitochondrial 1:173, 1:174, 1:176
24,25-$(OH)_2D_3$ 4:135, 4:140
Calcium excretion (vitamin D) 4:370, 4:371
Calcium flux (AT) 2:113, 2:119, 2:120
Calcium homeostatis 4:368
anticonvulsant therapy 3:17, 3:20, 3:21
bone-blood equilibrium 1:279, 1:282, 1:283, 1:284, 1:285, 2:143, 2:144, 2:148
CT therapy 2:147
kidney 1:285, 1:286, 2:148
osteoclast-mediated 1:67, 1:71
1,25-$(OH)_2D$ 2:146, 2:147
Calcium hormones
CT 2:147
PTH 2:145, 2:146
1,25-$(OH)_2D$ 2:145, 2:146
Calcium kinetics
CT-EHDP 1:255
CT-EHDP (^{47}Ca) 3:323, 3:324
osteoporosis 2:233, 2:235, 3:23, 3:24, 3:25, 3:27, 3:28, 3:29
postmenopause 4:175, 4:176, 4:177, 4:178
Calcium metabolism
bone marrow 2:245, 2:246
epiphyseal cartilage (^{45}Ca) 1:125, 1:126, 1:131, 1:134, 1:135
osteopetrosis (infantile) 3:135, 3:136, 3:139
Paget's disease 3:255
postmenopause 4:175, 4:178
vitamin D metabolites 1:24, 1:25, 1:26, 1:27, 1:28
Calcium (mitochondrial) 1:243
Calcium oxalate monohydrate 4:49, 4:50, 4:51, 4:53, 4:55, 4:58
Calcium phosphate 1:179
Calcium (plasma) 2:143
bone 1:284, 1:285, 1:286
CT 2:152
DPH/SV-treated rats 4:273, 4:274
EHDP-treated rats 4:122, 4:123, 4:126
hypercalcemia 2:163
1α-$(OH)_3$ treatment 1:16, 1:17, 1:18
Calcium pyroantimonate (CaP) 1:243, 1:244, 1:249
Calcium regulating hormones. see Calcitonin; Parathyroid hormone; 1,25-(OH)D
Calcium renal tubular reabsorption (vitamin D) 1:9, 1:12, 2:153, 2:154
Calcium (serum)
anticonvulsant therapy 4:44, 4:46
hypercalcitoninemia (MCT) 4:17, 4:18, 4:20, 4:22
1,25-$(OH)_2D_3$ therapy 4:340
Calcium storage 4:135, 4:138, 4:140
Calcium transport
bone 2:143, 2:144, 2:146, 2:148, 2:149
condylar cartilage 1:243, 1:249
GH 2:251, 2:253, 2:254
gut 2:143, 2:144, 2:146, 2:147
kidney 2:144, 2:148
PTH 2:143
1,25-$(OH)_2D_3$ 1:29, 1:30, 1:31, 1:32, 2:251, 2:252, 2:253, 2:254
24,25-$(OH)_2D_3$ 4:135, 4:140
Calcium (tubular reabsorption) 1:279, 1:285, 1:286
Calcium-binding factor 1:155
Calcium-binding proteins 1:179
Calcium-dependent processes 4:361
Calcium-phospholipid-phosphate ($Ca\text{-}PL\text{-}PO_4$) complexes
bone 4:151, 4:152, 4:154, 4:155
bone pericellular sites 2:113, 2:118, 2:119, 2:120
calcification 2:281, 2:282, 2:283
cartilage 1:115, 4:143, 4:144, 4:147, 4:149
tissue mineralization 1:137, 1:138, 1:139, 1:140, 1:141
Calcium-thiazides (Paget's disease) 3:224
Calcospherites 4:366
Calmodulin 4:361
Calvarial differentiation 1:75, 1:76, 1:78, 1:79
Cancer (breast)
hypercalcemia 2:162, 2:173, 2:174
osteolysis 4:364
Cancer (occult) 2:162
Cancer (prostaglandins) 2:169, 2:170
CaP. see Calcium pyroantimonate
Carbamazepine 4:271, 4:274
Carbohydrate containing substances (CSS) 2:265, 2:266, 2:271

Cartilage
APase 3:61, 3:63, 3:65, 3:67, 3:68, 3:74, 3:75
calcification 1:179, 1:183, 1:206, 1:207, 1:210
Cartilage (articular) 1:109, 2:50, 2:52
Cartilage (condylar)
APase 3:68, 3:74
calcification 1:243, 1:244, 1:245, 1:249
calcium distribution 4:143, 4:144, 4:147
growth 4:338, 4:339, 4:344
Cartilage (cryosections) 1:97, 1:100, 1:101, 1:102
Cartilage (epiphyseal)
APase 1:161, 1:162, 1:163, 1:164, 1:166, 1:167
^{45}calcium metabolism 1:125, 1:126, 1:127, 1:130, 1:131, 1:134, 1:135
circadian changes 2:60, 2:61
collagen 2:50, 2:52
Cartilage (epiphyseal) (cont.)
electron probe analysis 1:97, 1:98, 1:100, 1:101, 1:102
fractionation 1:126, 1:128, 1:129
matrix vesicles 1:98, 1:100
phosphorus concentration 1:100, 1:102
^{32}P-orthophosphate metabolism 1:125, 1:126, 1:127, 1:130, 1:131, 1:134, 1:135
Cartilage fluid (extracellular)
APase 1:158, 1:159
hypertrophic cell 1:155
Cartilage (growth)
cell kinetics (uremia) 3:191, 3:192, 3:193, 3:196
vitamin D_3metabolites *in vitro* 4:135, 4:136, 4:137, 4:138, 4:140
Cartilage (human articular) 1:115, 1:116, 1:117, 1:118
Cartilage (*in vitro*) 2:66
Cartilage matrix (noncalcified) 4:211, 4:213
Cartilage matrix (ultrastructure) 4:135, 4:136, 4:137, 4:138
Cartilage matrix vesicles 1:126, 1:199, 1:200, 1:201, 1:202, 1:203, 1:205, 1:207, 1:208, 1:209, 1:231
Cartilage mineralization
APase 3:67, 3:75
APase activity 3:61, 3:64, 3:65
apatitie crystals 1:109, 1:110, 1:112
glucocorticoids 2:267, 2:268, 2:267, 2:278
1,25-$(OH)_2D_3$ 4:339
Cartilage noncollagen protein 2:50, 2:52
Cartilage (rachitic growth) 1:199, 1:200, 1:201, 1:202, 1:203
Cartilage (rachitic growth plate) 1:193, 1:194, 1:195, 1:196
Cartilage (scorbutic) 1:205, 1:207, 1:208, 1:209, 1:210
Cell motility 1:59, 1:61, 1:62
Chemotaxis 2:174, 2:175
Chloromethylene diphosphonate. see Cl_2MDP
Cholecalciferol. see Dihydroxycholecalciferol; Hydroxyvitamin D_3; Vitamin D_3
Chondroblasts
APase activity 3:74, 3:75
condylar cartilage 1:243, 1:244, 1:245
glucocorticoids 2:267, 2:269, 2:276
1,25-$(OH)_2D_3$ 4:344
Chondrocalcinosis 1:85
Chondroclast census 2:60, 2:61
Chondrocyte mitochondria 1:173, 1:174, 1:176
Chondrocytes
APase activity 1:161, 1:162, 1:163, 1:166, 1:167, 3:75
cartilage (condylar) 1:243, 1:244, 1:245, 1:249
cartilage (epiphyseal) 1:98, 1:100
cartilage (scorbutic) 1:206, 1:208, 1:210, 1:211
matrix vesicles 1:83, 1:86, 1:90, 1:92
maturation 4:143, 4:144, 4:147, 4:149
ultrastructure 2:267, 2:268, 2:276
uremic animals 3:196, 3:197
vitamin D_3 metabolites 4:135, 4:136, 4:137, 4:138
1,25-$(OH)_2D_3$ therapy 4:338, 4:339, 4:344
Chondroprogenitor cells
APase activity 3:74
calcium 4:147, 4:149
1,25-$(OH)_2D_3$ 4:344
CION. see Corticosteroid-induced osteonecrosis
Circadian rhythms
collagen fractions 2:50, 2:51, 2:52
osteoblasts 3:51, 3:52
osteoclasts 2:60, 2:61
tetracycline labeling 3:53, 3:54

Cl_2MDP 3:228
  antiosteoclastic activity 4:326, 4:327
  biochemical effects 3:282, 3:283
  osteocyte activity 2:261, 2:262, 2:263
  PTH 4:362
Cl_2MDP therapy (MM) 4:163, 4:164, 4:165, 4:166, 4:167, 4:325, 4:326, 4:327
Cl_2MDP-treated rats 2:39, 2:41, 2:43, 2:47
Colchicine 2:184
Collagen 1:179
  abnormality (OI) 1:299, 1:300
  bone 4:95, 4:96, 4:97, 4:98, 4:99, 4:100
  cartilage (articular) 1:116
  cartilage (epiphyseal) 2:50, 2:52
  matrix metabolism 1:235
  products 3:255, 2:258
  pycnodysostosis 2:99, 2:105
  skin 4:95, 4:97, 4:98, 4:99
  type I 4:95, 4:96, 4:97, 4:98, 4:99, 4:100, 4:101
  type II 4:95, 4:96, 4:100
  type III 4:95, 4:96, 4:97, 4:100
Collagen cross links (OI) 4:95, 4:97, 4:98, 4:100
Collagen fibers
  osteocyte lacunae 1:326, 1:327
  osteons 1:329
  mineralized 1:220, 1:221
Collagen formation 3:255
Collagen fraction (circadian changes) 2:50, 2:52
Collagen fracture callus 1:319, 1:320, 1:322, 1:323
Collagen synthesis
  dichloromethylene bisphosphonate 4:369
  MAV-2(O) cultures 3:81, 3:82, 3:84, 3:86, 3:87, 3:88
  vitamin C deficiency 1:205, 1:209
Collagenase production 4:367, 3:369
Colony forming unit (CFU) 3:131, 3:132
Condylar cartilage. see Cartilage (condylar)
Condyles 3:74, 2:267, 2:268
Contractile proteins (matrix vesicles) 1:185, 1:189, 1:190, 1:227, 1:229, 1:232
Cortex blood flows 2:123, 2:124, 2:125, 2:126, 2:127, 2:128
Cortical bone formation 4:350, 3:351
Corticosteroid hypersecretion 4:69, 4:73, 4:74
Corticosteroid therapy. see also Glucocorticoids
  bone lipid metabolism 4:319, 4:320, 4:321, 4:322
  osteonecrosis 4:313, 4:314, 4:315, 4:316, 4:317, 4:319, 4:321, 4:322
  osteopenia 4:319, 4:322
  osteoporosis 1:303, 1:304, 1:305, 1:306, 1:307, 1:308, 4:319, 4:321, 4:322
  trabecular bone loss 1:308
Corticosteroids
  cartilage APase 3:67, 3:68, 3:74, 3:75
  hyperparathyroidism 3:308
Corticosteroid-induced osteonecrosis (CION) 4:313, 4:314, 4:315, 4:316, 4:317, 4:319
Cortisone acetate (bone formation) 3:199, 3:200, 3:201, 3:204, 3:205, 3:206
Crystallinity studies (fluoride) 2:3, 2:4, 2:5
CT. see Calcitonin
Cushing's syndrome (CS) 1:303, 1:304, 1:305
cyclic AMP (cAMP)
  hypercalcemia 2:163
  osteopetrosis (congenital malignant) 3:146
  osteopetrotic mice 3:129
  prostaglandins 2:167, 2:168
Cysteine concentrations (OI) 1:299, 1:300, 1:301
Cytoplasmic processes 1:56, 1:61

DBP. see Vitamin D binding protein
Dentin (interglobular) 2:17, 2:18, 2:20, 2:21
Dentine calcopherites 4:366
Dialysis osteodystrophy. see Osteodystrophy (dialysis)
Diaphyses (noninwaisted) 4:222
Diarthrodial joints 1:115, 1:116, 1:118
Diazepam-treated rats 4:271, 4:274
Dichloromethylene bisphosphonate 4:368
Dichloromethylene diphosphonate. see also Cl_2MDP; Diphosphonates; EHDP
  antiosteoclastic activity 4:326, 4:327
  Paget's disease 4:325, 4:326, 4:327, 4:328
1α,25 Dihyroxycholecalciferol. see 1α-$(OH)_2D_3$
1,25 Dihydroxyvitamin D. see 1,25-$(OH)_2D_3$
24,25 Dihydroxyvitamin D. see 24,25-$(OH)_2D$
24,25 Dihydroxyvitamin D_3. see 24,25-$(OH)_2D_3$
25,26 Dihydroxyvitamin D_3. see 25,26-$(OH)_2D_3$
Diphenylhydantoin (DPH) therapy 4:271, 4:272, 4:274
Diphosphonates. see also Amino hydroxypropylidene diphosphonate (APD); Chloromethylene Diphosphate (Cl_2MDP); Ethane hydroxydiphosphonate (EHDP); Sodium etidronate (EHDP)
  biochemical effects 3:282, 3:283
  bone metabolism 2:39, 2:40, 2:41, 2:42, 2:43, 2:44, 2:45, 2:46, 2:47, 2:48
  bone resorption inhibition 2:183, 2:184, 3:281, 3:282, 3:312, 3:313
  bone scan 3:243
  bone turnover 4:327
  calcification inhibtion 3:281
  calciphylactic response 1:219, 1:225
  collagenase production 4:367, 4:369
  complications 4:371
  EHDP 3:55, 3:57, 3:58, 3:59
  metabolism 3:283, 3:284
  osteolysis 2:263
  osteoporosis (immobilization) 2:261, 2:262, 2:263, 2:265
  PG production 4:369, 4:370
Disodium ethane hydroxy diphosphonate. see EHDP
Disodium etidronate. see EHDP
DNA
  circadian variations 250, 2:252
  synthesis 3:61, 3:82, 3:83, 3:86, 3:87
DNA-synthesizing bone cells 3:195, 3:196
Drift (osteoblastic) 4:218, 4:223
Drifts (bone modeling) 4:217, 4:218, 4:219, 4:220, 4:221

EGTA (ethylene glycol-bis β-amino ethyl ether] N N'-tetra acetic acid) 1:194, 1:195, 1:196
EHDP (ethane-hydroxy-diphosphonate)
  adverse effects 3:226, 3:227
  APase 3:321
  biochemical effects 3:225, 3:226, 3:282, 2:283, 3:302, 3:303, 3:319, 3:321, 3:323
  bone histomorphometry 3:291, 3:292, 3:293, 3:295
  fibroblast proliferation 3:55, 3:57, 3:58, 3:59
  hyroxyapatite binding 3:337, 3:338
  osteoblast generation 3:55, 3:57, 3:58, 3:59
  osteoclasts 3:309, 3:310, 3:312, 3:323
  Paget's disease 3:225, 3:226, 2:227, 3:228, 3:309, 3:310, 3:311, 3:312, 3:314, 3:317, 3:318, 3:321, 3:323, 3:324, 3:325
  safety 3:340
  skeletal effects (dogs) 3:289, 3:290, 3:291, 3:292, 3:293, 3:295, 2:296, 3:300
EHDP therapy
  adult hereditary bone dysplasia 3:11, 3:15
  heterotopic ossification 3:219, 3:227, 3:337, 3:338, 3:339, 3:340, 3:341
  osteoporosis 3:219
EHDP therapy (Paget's disease)
  antiosteoclastic activity 3:309, 3:312, 3:313, 3:314
  biochemical response 3:301, 3:302, 3:303, 3:323, 3:324
  bone histology 3:309, 3:310, 3:311, 3:312, 3:313, 3:314
  bone response 3:323, 3:324
  bone turnover 3:321
  calcification rates 3:309, 3:311, 3:313
  clinical effects (long-term) 3:303, 3:304, 3:305
  clinical response 3:317, 3:318
  indications 3:306
  management approaches 3:307
  use 3:224, 3:225, 3:226, 3:227, 3:228, 3:332, 3:345
EHDP-calcitonin therapy (Paget's disease) 1:251, 1:252, 3:323 ,3:324
  bone histology 1:257
  bone scans 1:257
  bone scintigraphy 4:103, 4:104, 4:105, 4:106, 4:107, 4:108, 4:109
  calcium balance 1:255, 1:258, 1:259
  calcium kinetics 1:255
EHDP-treated rats
  adrenal cortex hypertrophy 4:121, 4:122, 4:126
  bone mass 4:121, 4:122, 4:123, 4:125
  bone parameters 2:41, 2:43
  plasma calcium 4:122, 4:123, 4:126
  serum parameters 2:41, 2:43
Enamel hypoplasia
  hypocalcemia 2:20, 2:21
  hyperparathyroidism 2:20, 2:21
  rickets 2:17, 2:18, 2:20, 2:21
Enamel matrix (nonmelogenin components) 4:371
Endochondral ossification 1:319, 1:320, 1:321, 1:322, 1:323, 2:66, 4:65, 4:67
Endosteal bone. see Bone (endosteal)
Epiphyseal growth cartilage. see Cartilage (epiphyseal)
Epiphyseal growth plate. see Growth plate
Epiphysis 1:90, 1:109
Estrogen deficiency 3:5, 3:6, 4:1, 4:5
Estrogen status (postmenopause) 4:175, 4:176, 4:177, 4:178
Estrogen therapy 2:107, 2:205
Estrogens 2:183, 4:361
Ethane-hydroxy-diphosphonate. see EHDP
Ethylene glycol-bis (β-amino ethyl ether) N N'-tetra acetic acid). see EGTA

Fanconi syndrome 2:248
Femoral head 4:315
Femoral neck fractures 4:85, 4:86, 4:87, 4:88, 4:89, 4:90, 4:91
Femur
  blood flow (canine) 2:123, 2:124, 2:125, 2:126, 2:127, 2:128
  blood flow (NTON) 4:314, 4:315
  fractures 3:273, 3:275
  matrix vesicles 1:105, 1:106, 1:107, 1:108
FHH. see Hypercalcemia (familial hypocalciuric)
Flexure
  bone architecture 4:222, 4:223, 4:224, 4:225, 4:227
  bone modeling 4:219, 4:220, 4:221
  neutralization 4:221, 4:222, 4:223
  related phenomena 4:223, 4:224, 4:225, 4:226
Fluoride bone mineral content (osteoporosis therapy) 4:31, 4:32, 4:33, 4:34, 4:35, 4:36

Fluoride (mineral deposits) 2:3, 2:4, 2:6, 2:6, 2:7, 2:8, 2:9
Fluoride treatment 1:49, 1:50, 1:51, 1:52, 1:53
Fluoride-apatite interactions 2:3, 2:7, 2:8
Fluoride-calcium-dihydrotachysterol regimen (osteoporosis) 4:31, 4:32, 4:33, 4:34, 4:35
Fluorosis 1:49, 1:51, 1:52, 1:53
Fracture (bone modeling) 4:225, 4:226
Fracture callus
  lipids 1:319, 1:320, 1:321, 1:322
  matrix 4:61, 4:64, 4:65, 4:66, 4:67
Fracture healing
  EHDP therapy 3:318
  endochondral ossification 1:319, 1:320, 1:321, 1:322, 1:323, 2:66, 4:65, 4:67
  histology 3:20, 4:61, 4:65
  immobilization/nonimmobilization 4:61, 4:64, 4:65, 4:66, 4:67
Fracture induction (EHDP) 3:296, 3:300
Fractures
  femoral neck 4:85, 4:86, 4:87, 4:88, 4:89, 4:90, 4:91
  femur 3:273, 3:275
  hip 4:85, 4:90
  Paget's disease 3:271, 3:273, 3:275, 3:305
Freeze-fracture studies 1:89, 1:90, 1:91, 1:92
Freeze-replication 4:365

GAG. see Glycosaminoglycans
GH. see Growth hormone
Gla. see Glycoprotein
Glomerular filtration rate (GFR)
  hypercalcemia 2:155, 2:156
  1,25-$(OH)_2D$ — 25-$(OH)D_3$ therapy 4:256, 4:257, 2:259
Glucagon (bone resorption inhibition) 2:183, 3:224
Glucocorticoids
  bone resorption inhibition 2:183
  calcium uptake 3:205
  cartilage APase 367, 3:68, 3:74, 3:75
  cartilage response 2:267, 2:268, 2:276
  condylar cartilage 3:68, 3:74
  hypercalcemia 2:203, 2:204
  mandibular cartilage 3:206
  skeletal tissue ultrastructure 2:267, 2:268, 2:276, 2:278
Glycoprotein (Gla)
  bone matrix *in vitro* 2:71
  fracture callus matrix 4:61, 4:64, 4:66, 4:67
  glycolytic cycle 3:206
Glycosaminoglycans (GAG)
  bone matrix *in vitro* 2:71
  bone matrix (organic) 4:77, 4:78, 4:79, 4:80
  mineralization 4:211, 4:214, 4:215
  mineralization sites 4:77, 4:79, 4:80, 4:82, 4:83
Golgi apparatus 1:219, 1:220, 1:225
Growth. see Bone growth
Growth cartilage. see Cartilage (growth)
Growth hormone (intestinal calcium transport) 2:251, 2:252, 2:253, 2:254
Growth hormone (GH) — 1,25-$(OH)_2D_3$ 3:47, 3:48
Growth plate 1:155
  cartilage 1:193
  epiphysis 1:161, 1:162, 1:163, 1:190
  matrix vesicle calcification 1:189, 1:190, 1:192

HA. see Hydroxyapatite
Harris' lines 4:53, 4:55
Head levels (pageloid bone) 4:243, 4:244, 4:245, 4:246
Healing (alveolar bone) 1:185, 1:191. see also Fracture healing
Hematopoiesis (osteopetrosis) 3:102, 3:103
Hematopoietic cells 4:353, 4:355, 4:356
Hematopoietic stem cells (HSC) 3:131, 3:132
$^3\beta$-Hemisuccinate-25-OHD_3 3:43, 3:44, 3:45
Hemodialysis
  biochemical values 3:177
  bone histomorphometry 3:175, 3:176, 3:177, 3:178
  maintenance (children) 1:15
  1α-hydroxyvitamin D_3 therapy 1:15, 1:16, 1:17, 1:18, 1:19, 1:20
Heparin 2:182
Hereditary bone dysplasia (adult) 3:9, 3:10, 3:11, 3:313, 3:314, 3:15
Hexosamine elevations 4:61, 4:64, 4:65, 4:66, 4:67
Hexuronate 4:66, 4:67
Hip fractures 4:85, 4:90
Human calcitonin. see Calcitonin (human)
Human parathyroid fragment (hPTH 1—34) therapy 2:233, 3:23, 3:26, 3:29
Humeral diaphyses 4:349, 4:351
Hydrocortisone suppression test 2:163
Hydrolysine
  collagen 4:95, 4:96, 4:97, 4:100
  Paget's disease 3:255, 3:258
Hydrolytic enzymes (diphosphonate treatment) 2:43, 2:47
Hydroxyapatite (HA, OHAP) 1:123, 2:3, 2:8, 2:36
  binding (EHDP) 3:337, 3:338
  biological 1:179
  dissolution (diphosphonate) 2:46
  nucleation 1:149, 1:150, 1:151, 1:152, 1:180
Hydroxyapatite crystals
  bone mineral 2:36
  matrix vesicles 4:129, 4:130, 4:132
  paramagnetic centers 2:35
  Sudek's atrophy 4:305, 4:308, 4:310
Hydroxyapatite formation
  Ca-phospholipid-PO_4 complexes 1:137, 1:139, 1:140, 1:141
  inhibitors 1:183
  proteoglycans 1:181, 1:182
  synthetic 1:180
Hydroxyproline (OHP)
  Cl_2MDP (MM) 4:163, 4:166, 4:167
  CT-EHDP 1:251, 1:253, 1:254, 1:258, 1:259
  EHDP 3:321, 3:323
Hydroxyproline excretion 3:146
Hydroxyproline (plasma) (uremia) 4:297, 4:298, 4:299, 4:300, 4:301, 4:302
Hydroxyproline (urinary)
  Cl_2MDP therapy 4:325, 4:326
  EHDP therapy 3:301, 3:302, 3:303, 3:304
  HCT therapy 2:87, 2:88
  Paget's disease 3:219, 3:221, 3:301, 3:302, 3:303, 3:304, 3:305
^{3}(H)-25-Hydroxyvitamin D_3 4:362
1α Hydroxyvitamin D_3. see 1α-$(OH)D_3$
25-Hydroxycholecalciferol. see 25-HCC
25-Hydroxyvitamin D. see 25-OHD
25-Hydroxyvitamin D_3. see 25-OHD_3
Hypercalcemia. see also Hypercalciuria (idiopathic)
  anticonvulsant 4:46
  blood values 2:163, 2:164
  calcium homeostasis 2:143, 2:148, 2:149
  cancer (occult) 2:162
  causative factors 2:152, 2:153, 2:154, 2:155
  cyclic AMP 2:163
  differential diagnosis 2:161, 2:162, 2:163
  estrogen therapy 2:205
  GFR 2:155, 2:156
  glucocorticoids 2:203, 2:204, 2:205
  hydrocortisone suppression test 2:163
  hyperabsorption 1:288, 1:289
Hypercalcemia (cont.)
  hyperparathyroidism 2:161, 2:162, 2:204
  mechanisms 4:364
  milk alkali syndrome 2:162, 2:163
  Paget's disease 2:89
  parathyroidectomy 4:189, 4:190
  pathophysiology 2:151, 2:156, 2:157
  predictive tests 4:364
  PTH assay 2:163, 2:164
  radiologic investigation 2:164
  sarcoidosis 2:162
  steady/transient states 2:151, 2:152
  urine analysis 2:163, 2:164
  vitamin D intoxication 2:162
  vitamin D metabolite assay 2:164
Hypercalcemia (disequilibrium) 1:286, 1:287, 1:288
Hypercalcemia (equilibrium) 1:279, 1:280, 1:284
Hypercalcemia (familial hypocalciuric) (FHH) 2:162, 2:163
Hypercalcemia (malignant)
  bone metastases 2:173, 2:174, 2:175
  myeloma 2:175
  OAF 2:174, 2:175
  renal failure 2:191, 2:192, 2:195, 4:370
  tumors 2:173, 2:174, 2:175
Hypercalcemia treatment
  antihypercalcemic agents 2:185
  APD 4:363
  CT 2:207, 2:208, 2:209, 2:210, 2:211
  estrogens 2:203, 2:204, 2:205
  glucocorticoids 2:203, 2:204, 2:205
  mithramycin 2:199, 2:200, 2:201, 2:202
  phosphates 2:192, 2:195, 2:213, 2:214, 2:215
  prostaglandins 2:169, 1:170
Hypercalcitoninemia (vitamin D metabolism) 4:17, 4:19, 4:20, 4:21, 4:22
Hypercalciuria
  Cl_2MDP (MM) 4:163, 4:165, 4:167
  IH 3:39, 3:40, 3:41
  skeletal sarcoidosis 3:172
Hyperparathyroidism
  corticosteroid therapy 3:308
  dialysis ROD 2:218, 2:219, 2:220, 2:221
  lesions 1:15, 1:19, 1:20
  Paget's disease 3:260
  skeletal ROD 2:223, 2:229
  uremic bone disease 1:40, 1:41
  1,25-$(OH)_2D_3$ 1:43
Hyperparathyroidism (children) 1:15, 1:16, 1:17, 1:18, 1:19, 1:20
Hyperparathyroidism (primary) 1:279
  equilibrium hypercalcemia 1:280, 1:281, 1:284
  disequilibrium hypercalcemia 1:286, 1:287, 1:288
  hypercalcemia 2:161, 2:162, 2:204
  osteitis fibrosa cystica 4:187, 4:188, 4:190
Hyperparathyroidism (secondary)
  osteopetrosis 3:139
  uremia 3:191, 3:196, 3:197
Hyperphosphatemia
  adult hereditary bone dysplasia 3:9, 3:10, 3:13, 3:14, 3:15
  TPTX rats 2:258
  vitamin D (dialysis ROD) 2:217, 2:220
Hyperthyroidism
  bone formation rate 1:45, 1:46, 1:47
  bone remodeling 3:181, 3:182, 3:183, 3:184
  Paget's disease 3:306
Hyperuricemia 3:260
Hypocalcemia
  HCT 2:93, 2:94, 2:95, 2:96

Hypocalcemia (cont.)
hypoparathyroidism 2:18, 2:20
hypophosphatemia 2:20
osteopetrosis 3:143, 3:146
osteopetrosis (congenital) 3:143, 3:144, 3:146
osteopetrosis (infantile malignant) 3:135, 3:136
rickets 2:18, 2:20
SCT 2:93, 2:94, 2:95, 4:39, 4:40, 4:41, 4:42
TPTX rats 2:258
Hypoparathyroidism 2:17, 2:18, 2:20
Hyphophosphatemia (XLH)
adult hereditary bone dysplasia 3:9, 3:10, 3:11, 3:13, 3:14, 3:15
adult phosphate diabetes 3:36
anticonvulsant therapy 4:46
dentin 2:20, 2:21
HCT (Paget's disease) 2:93, 2:94, 2:95, 2:96
hypoparathyroidism 2:17, 2:18
matrix vesicles 1:85
osteomalacia 3:36
VDDR 2:20
VDRR 3:36, 4:249
Hypothyroidism
bone formation rate 1:45, 1:46, 1:47
bone remodeling 3:181, 3:182, 3:184
osteoid maturation 1:45, 1:46, 1:47

IH (idiopathic hypercalciuria). see Hypercalciuria (idiopathic)
Iliac bone biopsy 1:35, 1:36
Iliac crest
bone density 3:187, 3:188, 3:189
bone histomorphometry 4:231, 4:232, 4:233, 2:234, 2:235
lamellar thickness 4:291
Immobilization
bone repletion 1:269, 1:270, 1:271, 1:272, 1:273 1:274, 1:275
fracture healing 4:61, 4:65, 4:66, 4:67
Immunocytology 3:325, 3:236
Immunosuppressive therapy 1:145, 1:146, 1:147
Incisor eruption (*ia* rats) 3:108, 3:110, 3:111, 4:264, 4:265, 4:266, 4:267
Intermediary organization (IO). see also Skeletal intermediary organization 4:281, 4:282, 4:283, 4:284, 4:285, 4:286, 4:287, 4:288
Internodular matrix (mineralized) 4:211, 4:213, 4:214
Intracortical bone resorption (ROD) therapy 2:223, 2:224, 2:226, 2:227, 2:228, 2:229, 2:230
IO. see Intermediary organization
Itai-itai disease 2:247, 2:248, 2:250
IVNAA (*in vivo* neutron activation analysis). see Neutron activation analysis

Jejuno-ileal bypass (vitamin D deficiency) 2:77, 2:79, 2:80, 2:81

Kidney
calcium transport 2:143, 2:144, 2:146, 2:148
vitamin D 1:9

Label escape error model 4:237, 4:238, 4:239, 4:240, 4:241
Lamellar bone. see Bone (lamellar)
Lead levels (pagetic bone) 4:243, 4:244, 4:245, 4:246
Lipids
calcification 1:137, 1:138, 2:281, 2:282, 2:283
complexed 1:137, 1:138, 1:139, 1:140, 1:141
fracture callus 1:319, 1:320, 1:321, 2:322, 1:232
lipid-calcium interaction 1:185
Lysine hydroxylation (bone collagen) 4:95, 4:96, 4:97, 4:100
Lysosomal enzymes 3:123, 3:124
Lysosomes 1:58, 1:59
Lysozyme-inositol-triphosphatide complex 2:281, 2:282, 2:283
Lysozyme-phosphoinositide complexes 1:150, 1:152

Magnesium (bone) 2:257, 2:258, 2:259
Malabsorption bone disease 3:165, 3:168, 3:169
Marrow. see Bone marrow
Matrix vesicle calcification 1:186, 3:206
acidic phospholipids 1:143, 1:146
aortic 1:213, 1:216
APase 1:165, 1:167
ATPase 1:169, 1:170
^{45}calcium accumulation 1:193
epiphyseal growth plate 1:189
freeze-fracture studies 1:83, 1:85, 1:86, 1:89, 1:90, 1:91, 1:92
osteomalacia 4:129, 4:132, 4:133
rachitic growth plate 1:199, 1:200, 1:201, 1:202, 1:203
rachitic growth plate cartilage 1:193, 1:195, 1:196
Matrix vesicle calcium storage 4:135, 4:138, 4:140
Matrix vesicle enzymes (osteosarcoma) 1:227, 1:229, 1:232
Matrix vesicle formation 1:82, 1:83, 1:85, 1:210, 1:211
Matrix vesicle fractions (bone) 3:210, 3:211, 3:213
Matrix vesicle isolation (nonenzymatic) 1:125, 1:126, 1:127, 1:128, 1:129, 1:130, 1:131, 1:134, 1:135
Matrix vesicle origin 1:83, 1:90, 1:92
Matrix vesicle plasma membrane 1:119, 1:120, 1:123
Matrix vesicle reconstitution 1:169, 1:170
Matrix vesicles 1:155, 1:157, 1:158
alveolar bone 1:119, 1:120, 1:123
bone 3:210, 3:211, 3:312, 3:214
calciphylaxis 1:225
cartilage (condylar) 1:243, 1:244, 1:249
cartilage (epiphyseal) 1:98, 1:100
cartilage (human articular) 1:115, 1:118
cartilage (various) 1:126, 1:199, 1:200, 1:201, 1:202, 1:203, 1:205, 2:207, 1:208, 1:209, 1:231
DOC extraction 1:170
epiphyseal growth plates 1:90
extracellular 1:185, 1:186, 1:189, 1:191, 1:227, 1:231, 1:232
growth plate 1:89, 1:90, 1:92
healing sockets 1:185
MAP size 1:190, 1:192
mineralization 1:109, 1:110
osteopetrosis 1:240
osteosarcoma 1:227, 1:229, 1:231
purification 3:309, 3:312
reconstituted 1:169
scorbutic cartilage 1:205, 1:208, 1:209, 1:210
ultrastructure 1:105, 1:107, 1:108
MAV-2(O) virus. see Myeloblastosis-associated virus-2 (osteo)
MCN. see Multiple chained neutralizing phenomena
Mean wall thickness (MWT)
trabecular bone 4:113, 4:114, 4:115, 4:116, 4:117, 4:118
trabecular bone packets 3:182, 3:183, 3:184
Medullary carcinoma of the thyroid (MCT) 4:17, 4:18, 4:19, 4:20, 4:22
Membrane function (calcification) 1:143, 1:144, 1:145, 1:146
Membrane-associated particles (MAPS) 1:89, 1:92
Membranes (biologic calcification) 1:149
Metabolic bone disease
malabsorption 3:165, 3:168, 3:169
privational 3:165, 3:168, 3:169
Metabolic rhythms (rat skeleton) 2:60, 2:61
Metaphysis
proximal tibial 4:349, 4:351
uremic animals 3:195, 3:196, 3:197
weightlessness (changes) 4:347, 4:351
weightlessness (simulated) 4:69, 4:71, 4:73, 4:74
Metastases (bone) 2:169, 2:170
Metastases (skeletal) 2:199, 2:200, 2:201, 2:202
Microradiography 1:49, 1:50
Microradioscopy technique (bone resorption) 2:223, 2:224, 2:225, 2:226, 2:228, 2:229, 2:230
Microsphere (bone blood flow)
canine femurs 2:123, 2:124, 2:125, 2:126, 2:127, 2:128
geese femurs 4:313, 4:314, 4:315, 4:316, 4:317
Microspheres (calcereous) 4:365
Milk alkali syndrome (hypercalcemia) 2:162, 2:163
Mineral balance studies (osteopetrosis) 3:136, 3:139
Mineral deposits
amorphous 1:119, 1:120, 1:123
CT administration 2:119
fluoride 2:3, 2:5, 2:6, 2:7, 2:8, 2:9
Mineral homeostasis (PTH) 2:257, 2:258, 2:259, 2:260
Mineral metabolism
osteopetrosis 3:144
skeletal sarcoidosis 3:171
TPTX rats 1:314
Mineral nucleation 1:155, 1:158
Mineral ultrastructure (embryonic bone) 1:105, 1:106, 1:107, 1:108
Mineralization, see also Calcification, Crystallization 1:119, 1:120, 1:193
bone 4:211, 4:14, 4:215
bone studies (ultrastructural) 1:231
Ca-PL-PO_4 4:151, 4:152, 4:153, 4:155
cartilage 1:109, 1:110, 1:112, 4:211, 4:214, 4:215
circadian rhythms 2:60
collagen (bone) 3:27
CT-EHDP therapy 1:258
diphosphonate-treated rats 2:41
fracture healing 1:321, 1:322, 1:323
matrix 1:220, 1:222
matrix vesicles 1:83, 1:85, 1:86, 1:102, 1:109, 1:110
matrix vesicles (extracellular) 1:227, 1:229
microscopic study 1:106, 1:107
proteoglycans 4:67
VDRR 3:35, 3:36
vitamin D sterols 2:11
tissue (Ca-PL-PO_4 complexes) 1:137, 1:138, 1:139, 1:140, 1:141
Mineralization nodules
histochemical studies 4:77, 4:79, 4:80, 4:82, 4:83
x-ray microanalysis 4:211, 4:212, 4:213, 4:214, 4:215
Mineralization rate 1:139, 1:140
Mineralization-inhibition (EHDP) 3:291, 3:295, 3:296
Mineralized tissue (simulated weightlessness) 4:69, 4:71, 4:73, 4:74
Minimum effective strain (MES) 4:226

Mithramycin (bone resorption) 2:184, 2:185
Mithramycin (breast cancer)
bone metastases 2:199, 2:200, 2:201, 2:202
hypercalcemia 2:201
Mithramycin therapy (Paget's disease) 3:307, 3:223, 3:224, 3:332
biochemical effects 3:343, 3:345
pain relief 3:343, 3:344, 3:345
spine 3:332
Mitochondria
calcium concentration 1:102
calcium efflux 1:173, 1:174, 1:175
calcium loss 1:199, 1:200, 1:203
calcium storage 4:135, 4:137, 4:138, 4:140
chondrocytic calcification 1:243, 1:245, 1:249
Mitochondrial granules 1:100, 1:102, 1:224, 1:225
MM. see Multiple myeloma
Molar eruption (*in* rats) 3:108, 3:110, 3:111
Multiple chained neutralizing phenomena (MCN)
quantum effects 4:283, 4:287
skeletal organization 4:282, 4:283
Multiple myeloma (MM)
Cl_2MDP therapy 4:163, 4:164, 4:165, 4:166, 4:167
SCT Δ Ca test 4:39, 4:41, 4:42
Muscle activity (bone curvatures) 4:223, 4:225
MWT. see Mean wall thickness
Myeloblastosis-associated virus (MAV-2(0))
avian osteopetrosis 1:235, 1:236, 1:238, 1:241, 1:242
protein synthesis 3:81, 3:82, 3:84, 3:86, 3:87, 3:88
Myeloma cells (OAF) 2:175
Myeloma (hypercalcemia) 2:175
Myeloproliferative disorders
osteopetrosis (avian) 1:235, 1:236, 1:238, 1:241, 1:242
osteopetrosis (infantile) 3:135, 3:136, 3:139, 3:140
Myosin (osteosarcoma) 1:227, 1:229, 1:232

NCBP. See Noncollagenous bone protein
Nephrectomy (1,25-(OH)2D production) 4:333, 4:334, 4:335, 4:336
Nephron mass reduction ($1,25\text{-}(OH)_2D_3$ 4:333, 4:334
Necrotic bone. see Bone (necrotic)
Nephrotic syndrome (vitamin D metabolism) 4:7, 4:11, 4:12, 4:13, 4:361
Nerve compression syndrome 3:333
Neutron activation analysis (IVNAA) 4:169, 4:170, 4:172
Noncollagenous bone proteins (NCBP)
apatite-extracted 4:158, 4:159, 4:160
Gla-containing 4:157, 4:159, 4:160
NTON (nontraumatic osteonecrosis). see Osteonecrosis (nontraumatic)
Nucleation
apatitic 1:109
hydroxyapatite 1:179, 1:180
mineral 1:155, 1:158
Nucleating systems 1:179, 1:180, 1:181, 1:182, 1:183

OAF. see Osteoclast activating factor
Octacalcium (OCP) 2:7, 2:8
Odonta (incisal) 3:110
OHP. see Hydroxyproline
Oophorectomy (^{45}Ca calcium metabolism) 4:175, 4:178
Orthophosphate (pi) 1:195
Ossification 3:199, 3:200
arthroplasty (heterotopic) 2:219, 3:337, 3:338, 3:339, 3:340, 3:341
Ossification (cont.)
endochondral 1:319, 1:320, 1:321, 1:322, 1:323, 2:66, 4:65, 4:67
Osteitis deformans (Paget's disease) 3:219, 3:230, 3:239
Osteitis fibrosa cystica 4:187, 4:188, 4:190
Osteitis fibrosa (therapy)
$1\alpha(OH)D_3$ 1:17
1α-HCC (ROD) 2:217
1,25-D (ROD) 2:223, 2:225, 2:227, 2:228, 2:229, 2:230
Osteitis fibrosis
dialysis osteodystrophy 4:26
ROD 2:223, 2:225, 2:227, 2:228, 2:229, 2:230
uremic bone disease 1:39, 1:41, 1:43, 1:44
Osteoarthritis
Ca-PL-Po_4 complexes 4:151,4:152, 4:154, 4:155
matrix vesicles 1:85
Paget's disease 3:275, 3:276
Osteoblast
appositional rate 3:314
bone balance regulation 4:1, 4:4, 4:5
calcium depletion 1:274, 1:275
circadian rhythms 3:51, 3:52
generation 3:55, 3:57, 3:58, 3:59
mineral deposits 1:119, 1:120, 1:123
mineral structure 4:69, 4:73
PHA-P administration 4:196, 4:197
Pi-$1,25\text{-}(OH)_2D_3$ 3:162, 3:163
post weightlessness 4:347, 4:349, 4:350, 4:351
PTH 3:124, 3:129
Sudek's atrophy 4:306, 4:308, 4:309, 4:310
VDRR 3:31, 3:32, 3:35, 3:36
weightlessness 4:69, 4:73
Osteoblastoma 1:235, 1:241
Osteocalcin. see also Beta-glycerophosphate 4:157, 4:159, 4:160
Paget's disease 3:258, 3:259
Osteoclast Activating Factor (OAF) 2:173
bone resorption activation 2:181
hypercalcemia (malignant) 2:174, 2:175
lymphocytes 2:175
MM 4:41, 4:42
myeloma cells 2:175
prostaglandins 2:175, 2:176
Osteoclast activity
anticonvulsant therapy 4:46
EHDP-treated rats 2:41, 2:43, 2:46
incisor eruption 4:266, 4:267
osteopetrosis 4:266, 4:267
Osteoclast behavior *in vitro* 4:367, 4:371
Osteoclast inclusions 3:235, 3:236
Osteoclast reduction
bone repletion 4:201
Cl_2MDP 4:163, 4:166, 4:167
EHDP 3:323
Osteoclastic drift 4:223
Osteoclastopoiesis
blood monocytes 4:365
stem cells 3:131, 3:132
Osteoclasts
activation 2:179
avian osteopetrosis 1:241
bone repletion 1:274, 1:275, 4:201, 4:203, 4:205, 4:206, 4:207
bone resorption 1:67, 2:178, 2:179
calvarial 4:367
circadian rhythms 2:60, 2:61
disintegration 4:205, 4:206
fate 4:201, 4:207, 4:208
function defect (osteopetrosis) 3:123, 3:124, 3:135, 3:140
Osteoclasts (cont.)
increase (PHA-P administration) 4:193, 4:194, 4:196, 4:197 4:198
inefficiency 3:197
morphometry 1:68
osteopetrosis 3:117, 3:119, 3:120, 3:143, 3:146
osteoporosis 4:2, 4:4
Paget's disease 3:236, 3:309, 3:310, 3:312
Pi-$1,25\text{-}(OH)_2D_3$ 3:163
postweightlessness 4:347, 4:349, 4:350, 4:351
proliferation 3:99, 3:301, 3:102, 3:103
PTH-cultured 1:67, 1:70, 1:71, 1:73, 1:74, 4:365
resorptive activity (PTH) 3:143, 3:146, 3:147, 3:148
ruffled border (osteopetrosis) 4:263, 4:264, 4:265, 4:266, 4:267
sodium salicylate treatment 4:367
spleen cell transfer 3:110, 3:114
Sudek's atrophy 4:305, 4:306, 4:307, 4:308, 4:309, 4:310
ultrastructure 3:123, 3:124, 3:129, 3:235
Osteocyte activity (immobilization osteoporosis) 2:261, 2:262, 2:263, 2:265
Osteocyte lining cell complex (CT) 2:113, 2:114, 2:115, 2:118, 2:119
Osteocytes
Cl_2MDP 2:262, 2:263, 2:265
immobilization osteoporosis 2:261, 2:262, 4:69, 4:73
microtubules 1:59, 1:61
PTH 1:55, 1:56, 1:58, 1:59, 1:61, 1:62
Sudek's atrophy 4:305, 4:308, 4:310
Osteodensitometry 4:363
Osteodystrophy (dialysis)
aluminum toxicity 3:177, 3:178
iPTH effect 3:177, 3:178
osteitis fibrosa 4:26
vitamin D metabolites 2:217, 2:218, 2:219, 2:220, 2:221, 2:223, 2:224, 2:225, 2:226, 2:227, 2:228, 2:229, 2:230, 4:25, 4:28
Osteodystrophy (renal) (ROD) 1:39, 1:40
calcium oxalate deposition 4:58
matrix vesicles 1:85
oxalosis 4:49
serum aluminum 3:177, 3:178
vitamin D metabolism 4:336
vitamin D metabolites 2:217, 2:218, 2:219, 2:220, 2:221, 2:222, 2:223, 2:224, 2:225, 2:226, 2:227, 2:228, 2:229, 2:230
Osteodystrophy (renal juvenile) 4:255, 4:256, 4:257, 4:258, 4:259, 4:260, 4:261
Osteogenesis imperfecta (OI)
collagen 4:95, 4:96, 4:97, 4:98, 4:99, 4:100
urinary amino acids 1:299, 1:300, 1:301
Osteoid calcification 4:130, 4:132
Osteoid dynamics (anti-convulsant therapy) 1:45, 1:46, 1:47, 2:77, 2:80, 2:81
Osteoid maturation 1:45, 1:46, 1:47
periosteal 1:273, 1:274
Osteoid measurements (EHDP therapy) 3:312, 3:313
Osteoid parameters (femoral neck fractures) 4:87, 4:88, 4:89, 4:90
Osteoid surface 4:232, 4:233, 4:234, 4:300
Osteoid tissue 3:291, 4:211, 4:212
Osteoid volume 4:232, 4:233, 4:234, 4:235
Osteolysis
anistropic 1:55, 1:62

Osteolysis (cont.)
breast cancer 4:364
osteocytic 2:263, 3:14, 3:15
periosteocytic 1:51, 1:53, 1:55, 1:58, 1:61, 1:62, 1:325, 1:331, 1:333
Osteolytic lesions (Cl_2MDP therapy) 4:164, 4:165, 4:166, 4:167
Osteomalacia
diagnosis 2:85
EHDP 3:314
femoral neck fractures 4:85, 4:86, 4:89, 4:90
hypercalcemic 4:370
hypophosphatemia 3:36, 4:249, 4:250, 4:251
itai-itai disease 2:248
matrix cell calcification 4:129, 4:130, 4:132, 4:133
VDDR 1:10, 2:17, 2:18, 2:20, 2:21
Osteomalacia (anticonvulsant) 1:45, 4:370
bone formation rate 1:46, 1:47
pseudohypoparathyroidism 4:269, 4:274
vitamin D_3 therapy 2:83, 2:85
Osteomalacia (hypophosphatemic VDRR) 4:249, 4:250, 4:251
Osteomalacia (ROD) 1:12, 1:38, 1:43
dialysis ROD 3:177, 3:178
therapy 2:217, 2:220, 2:223, 2:227, 2:230
Osteomalacia (vitamin D deficiency) 1:10, 1:11, 3:165, 3:168, 3:169
diagnostic features 2:83, 2:85
histological features 2:85, 2:86
1,25-$(OH)_2D_3$ 1:10, 1:11, 2:83, 2:85, 3:165, 3:168, 3:169
Osteonecrosis
Ca-PL-PO_4 complexes 4:151, 4:152, 4:153, 4:154, 4:155
steroid-induced 4:319, 4:321, 4:322
Osteonecrosis (nontraumatic) (NTON)
bone blood flow 4:313, 4:314, 4:315, 4:317
corticosteroid therapy 4:317
Osteonectin 4:159, 4:160
Osteopenia. see also Osteoporosis
adult 4:287
anticonvulsant therapy 4:43, 4:44, 4:45
child 4:286
corticosteroid therapy 4:319, 4:322
senile skeletal 1:35, 1:36, 1:37, 1:38
skeletal sarcoidosis 3:171, 3:172, 3:173
VDRR 4:251
Osteopetro-rickets 3:91, 3:92, 3:93, 3:94, 3:95, 3:96, 3:97
Osteopetrosis
avian 1:235, 1:236, 1:238, 1:241, 1:242
congenital 3:78, 3:79
congenital (benign) 3:91, 3:99, 3:102
congenital (*ia* rat) 3:117, 3:118
congenital (malignant) 3:143, 3:144, 3:145, 3:146
congenital (*op* rat) 3:92, 3:96
congenital (*tl* rat) 3:92, 3:94, 3:96, 3:97
ia rats 3:107, 3:108, 3:110, 3:11, 3:114
ia/ia rats 4:264, 4:265, 4:266
malignant 3:91, 3:99, 3:100, 3:101, 3:102
malignant (infantile) 3:135, 3:136, 3:139, 3:140
mammalian 2:33
mi mice 3:123
mi/mi mice 3:151, 3:152, 3:153, 4:263, 4:264, 4:265
neonatal 1:135, 1:336
osteopetro-rickets 3:91, 3:92, 3:95, 3:96
pycnodysostosis 2:99, 2:104
Osteopetrosis treatment
bone marrow transplants 2:36
parabiosis cure 3:78, 3:79, 3:91, 3:92, 3:97, 3:108, 3:131, 3:132
Osteopetrosis treatment (cont.)
PTH 3:135, 3:136, 3:137, 3:139, 3:140
PTH infusion 3:145, 3:146
Osteoplasis 1:52, 1:53
Osteoporosis
bone histomorphometry 1:35, 3:27, 3:29
bone turnover 3:23, 3:24, 3:25, 3:26, 3:27, 3:29
bone volume 2:107
calcium absorption 2:233, 2:234, 2:235, 2:236, 2:237, 3:23, 3:27, 3:29
calcium deficiency 4:126
calcium (total body) 4:169, 4:170, 4:172
coupling 3:4, 3:5, 4:1
estrogen deficiency 3:5, 3:6
femoral neck fracture 4:91
osteoclasts 4:2, 4:4
pathogenesis 3:29, 4:1, 4:5
skeletal alterations 4:69, 4:73
TBD 1:35, 1:36, 1:37, 1:38
TB mass 2:108, 2:109
Osteoporosis (corticosteroid-induced) (CS-OP) 1:303, 1:304, 1:305, 1:306, 1:307, 1:308
female 4:169, 4:172
femoral neck fractures 4:91
immobilization 2:261, 2:262, 2:263, 2:265
infantile 3:139, 4:69, 4:73
involutional 3:23, 3:26, 3:29
postmenopausal 2:107, 2:108, 3:3, 3:4, 3:5, 3:6, 4:178
senile 4:285, 4:286
Osteoporosis treatment
calcium 4:31, 4:32, 4:33, 4:34, 4:35, 4:36
corticosteroid 4:319, 4:320, 4:322
CT 2:107, 2:108
diphosphonates 3:225
EHDP 3:219
estrogen 2:107
fluoride 4:31, 4:32, 4:33, 4:34, 4:35, 4:36
hPTH 1–34 3:23, 3:26, 3:29
phosphate-CT 2:108, 2:109, 2:110
PTH 2:108, 2:110, 3:144, 3:145, 3:148
Osteoprogenitor cells
PHA-P 4:193, 4:196, 4:197, 4:198
uremic animals 3:194, 3:195, 3:196, 3:197
Osteosarcoma
actin 1:227, 1:232
enzymatic activities 1:191
extracellular matrix vesicles 1:227
Paget's disease 3:250
primary bone formation 1:228, 1:229
Osteosclerosis 2:99
Oxalosis (primary) 4:49, 4:50, 4:51, 4:53, 4:55, 4:58
Oxygen (mitochondrial calcium release) 1:173, 1:174, 1:176

Paget's disease 2:131, 3:261, 4:243
acid phosphatase 3:259
anatomical distribution 3:239, 3:240
APase 3:219, 3:221, 3:301, 3:302, 3:303, 3:304, 3:305
biochemical changes 3:260
biochemical markers 3:255, 3:256, 3:257, 3:258, 3:259
bone blood flow 3:263, 3:267
bone formation/resorption 4:3, 4:4
bone pain 3:269, 3:302
bone remodeling 3:243
bone scans 3:240, 3:243, 3:248, 3:253
calcium metabolism 3:255
calcium space 3:268
collagen 3:255, 3:258
Paget's disease (cont.)
complications 2:89, 2:90
coupling factor 3:5
deformity 3:271
diagnostic features 2:88, 3:219, 3:220, 3:221
ESR 3:260
glycoprotein 3:259
hyperthyroidism 3:306
malignancies 3:76, 3:278
marrow (vascular) 3:239
mineralization defect 1:258
morphology 3:235, 3:236
OHP 3:301, 3:302, 3:304, 3:305
orthopedic aspects 3:271, 3:275, 3:276, 3:278
osteitis deformans 3:219, 3:230, 3:239
osteoarthritis (secondary) 3:275, 3:276
osteocalcin 3:258, 3:259
osteosarcoma 3:250
pathological fractures 3:271, 3:273
procollagen 3:255, 3:258
proline iminopeptidase 3:259
pseudouridine excretion 3:260
PTH function 3:260
PTH secretion 3:301, 3:305, 3:306
radiology 3:243, 3:244
relapses 3:228
scapular involvement 3:250, 3:252
sites 3:250, 3:251
skeletal bloodflow 3:268
skeletal involvement 3:239
urine calcium 3:259
Paget's disease (epidemiology) 3:219
Australia 3:232
Britain 3:231, 3:232
environmental 3:239
Europe 3:231
United States 3:232, 3:233
Paget's disease (etiology) 3:219, 3:233, 3:235, 3:236
Paget's disease (management)
analgesics 3:222
calcium-thiazides 3:224
Cl_2MDP 4:325, 4:326
CT 3:19, 3:20, 3:222, 3:223, 3:253, 3:267, 3:269, 3:307, 3:317, 3:319, 3:320, 3:332
CT-EHDP 1:251, 1:252, 1:253, 1:255, 1:257, 1:258, 1:259, 3:323, 3:324, 3:332
diphosphonates 3:224, 3:225, 3:253, 3:332
diphosphonates-CT 3:228
EHDP 3:225, 3:226, 3:227, 3:309, 3:310, 3:311, 3:312, 3:313, 3:314, 3:317, 3:318, 3:321, 3:323, 3:324, 3:325
EHDP-CT 4:103, 4:108
HCT 2:87, 2:88, 2:89
mithramycin 3:307, 3:223, 3:224, 3:332, 3:343, 3:344, 3:345
SCT 4:22
surgery 3:270, 3:271, 3:275, 3:276
Paget's disease (monostotic) 3:253
Paget's disease (spine) 3:327, 3:239, 3:268
PAO technique. see Potassium-pyroantimonate-osmium technique
Parabiosis (osteoporosis) 3:78, 3:79, 3:91, 3:92, 3:97, 3:107, 3:108, 3:131, 3:132
Paraparesis 3:333
Parathormone 4:341. see also Parathyroid hormone (PTH)
Parathyroid adenomas 3:305
Parathyroid extract (PTE) treatment
bone coupling 2:132, 2:133, 2:134
bone parameters 1:313, 1:314
TPTX 1:316, 1:317
Parathyroid function 3:260

Parathyroid hormone (PTH)
anticonvulsant osteomalacia *4*:270
bone cell treatment *1*:68, *1*:70, *1*:74, *1*:78
bone coupling *2*:131, *2*:132
bone repletion *1*:275
bone resorption *2*:143, *2*:146, *2*:180, *2*:229, *4*:467, *4*:368
calcium balance *2*:145, *2*:146
^{45}calcium release *3*:118, *3*:119, *3*:120
calcium transport *2*:143, *2*:146
Cl_2MDP *4*:364
CT-EHDP therapy *1*:255
DPH inhibition *4*:273, *4*:274
hypercalcemia *2*:163, *2*:164
^{125}I-labeled *1*:263, *1*:264, *1*:265, *1*:266
metabolism *2*:25, *2*:26, *2*:27, *2*:28, *2*:29, *2*:30
mineral homeostasis *2*:257
osteoblast response *3*:124, *3*:129
osteoclasts *1*:67, *1*:70, *1*:72, *1*:73, *1*:74
osteocytes *1*:55, *1*:58, *1*:59, *1*:61, *1*:62
osteogenic progenitor cells *4*:368
osteopetrosis (congenital malignant) *3*:145, *3*:146
osteopetrosis (infantile) *3*:135, *3*:136, *3*:137, *3*:139, *3*:140
osteoporosis therapy *2*:108, *2*:110
Paget's disease *3*:301, *3*:305, *3*:306
pseudoparathyroidism *4*:362
renal tubular absorption *2*:154
ROD therapy *3*:78
1,25-$(OH)_2$D production *2*:223, *2*:228, *4*:335, *4*:336
1,25-$(OH)_2$D--25-$(OH)D_3$ *4*:256, *4*:257, *4*:259
(Parathyroid hormone (hPTH 1--34) *3*:23, *3*:24, *3*:25, *3*:26, *3*:27, *3*:29
Parathyroid hormone (immunoreactive)
dialysis osteodystrophy *3*:177, *3*:178
DPH *4*:273, *4*:274
hypercalcitoninemia (MCT) *4*:17, *4*:19, *4*:20, *4*:21
osteoclasts *4*:201, *4*:207
osteopetrosis *3*:143, *3*:146
SV-treated rats *4*:273, *4*:274
1,25-$(OH)_2D_2$ *1*:16, *1*:18
24,25-$(OH)_2D_3$ *2*:12, *2*:14
Parathyroid hormone (plasma)
hyperphosphatemia *2*:220, *2*:221
vitamin D therapy *4*:25, *4*:26, *4*:29
Parathyroid hormone 28--48 (human) *4*:329, *4*:330, *4*:331, *4*:332
Parathyroid hyperfunction (osteitis fibrosa) *4*:187, *4*:190
Parathyroid hyperplasia (cortical remodeling sites) *4*:353, *4*:354, *4*:355, *4*:356, *4*:357
Parathyroid-osteoclast axis defect *3*:143
Parathyroidectomy
APase-PHP *4*:297, *4*:302
EHDP *4*:121, *4*:122, *4*:123, *4*:125, *4*:126
PTH *2*:257, *2*:258, *2*:259, *2*:260
Parathyroidectomy (partial) *4*:187, *4*:188, *4*:189, *4*:190
Periosteal bone formation
immobilization *1*:271, *1*:274
weightlessness *4*:347, *4*:349, *4*:350
Periosteal bone resorption (ROD therapy) *2*:223, *2*:225, *2*:226, *2*:227, *2*:228, *2*:229, *2*:230
Periosteocytic lacunae *1*:49, *1*:50, *1*:52, *1*:53, *1*:325, *1*:330
Periosteocytic osteolysis *1*:55, *1*:58, *1*:61, *1*:62
PG, see Prostaglandins
Phagocyte defect (osteopetrosis) *3*:135, *3*:139
PHA-P/ see *β*-hytohemagglutinin-P
PHP levels (uremia) *4*:299, *4*:300, *4*:301
phenotypes (osteopetrosis) *3*:143, *3*:148
Phosphatase activity *1*:159, *1*:193, *1*:194
Phosphate
anticonvulsant therapy *4*:44, *4*:46
bone resorption inhibition *2*:183, *2*:184, *3*:279
Phosphate (inorganic) *2*:213, *2*:214, *2*:215, *4*:363
Phosphate (plasma)
vitamin D metabolite therapy *2*:219, *2*:220
vitamin D therapy *4*:25, *4*:28, *4*:29
Phosphate (renal) *3*:39, *3*:40, *3*:41
Phosphate therapy
IH patients *3*:39, *3*:40, *3*:41
malignant hypercalcemia *2*:213, *2*:214, *2*:215, *2*:192, *2*:195
renal failure *2*:192
Phosphate-calcitonin therapy
osteoporosis *2*:107, *2*:108
osteoporosis (postmenopausal) *2*:108, *2*:109, *2*:110
Phosphate — 1,25-dihydroxyvitamin D treatment (VDRR) *3*:159, *3*:160, *3*:162, *3*:163
Phosphate — vitamin D metabolite therapy *1*:24, *1*:25, *1*:27, *1*:28
Phosphoethanolamine concentrations (OI) *1*:299, *1*:300, *1*:301
Phosphoenolpyruvate (PEP) *1*:173, *1*:174, *1*:175, *1*:176
Phospholipases *1*:141
Phospholipid composition *1*:125, *1*:126, *1*:130
Phospholipid extracts *1*:170, *1*:171
Phospholipids (acidic) *1*:143, *1*:145, *1*:146, *1*:216
Phosphorus concentrations
bone *2*:257, *2*:258
epiphyseal cartilage *1*:100, *1*:102
plasma *1*:17, *1*:18
serum (MCT) *4*:17, *4*:18, *4*:20
Phosphorus (dietary) *4*:333, *4*:334, *4*:335, *4*:336
PHP (plasma hydroxproline peptide-bound) *4*:297, *4*:298, *4*:299, *4*:300, *4*:301
Phytohemogglutin-P (PHA-P) (bone) *4*:193, *4*:194, *4*:195, *4*:196, *4*:197
Plasma . . . see . . . (plasma)
Plasma membrane
matrix vesicles *1*:119, *1*:120, *1*:123, *1*:183, *1*:186, *1*:189
osteoblast *1*:119, *1*:120, *1*:123
^{32}P-orthophosphate metabolism (^{32}Pi) *1*:125, *1*:126, *1*:127, *1*:131, *1*:134, *1*:135
Potassium pyroantimonate studies *1*:199, *1*:203
Potassium-pyroantimonate-osmium (PAO) technique
calcium complex distribution *4*:143, *4*:144, *4*:147, *4*:149
calcium distribution (cartilage) *4*:135, *4*:136, *4*:137, *4*:138
cartilage calcification *1*:243, *1*:244, *1*:245, *1*:249
Procollagen *3*:255, *3*:258
Proline iminopetidase *3*:259
Proline transport *3*:82, *3*:83, *3*:84
Prostaglandin synthetase inhibitors *2*:167
Prostaglandins (PG)
bone metastases *2*:169, *2*:170
bone resorption *2*:167, *2*:168, *2*:169
bone resorption activation *2*:181
cAMP production *2*:167, *2*:168
diphosphonates *4*:369, *4*:370
hypercalcemia (malignant) *2*:169, *2*:170
OAF *2*:175, *2*:176
osteoclast motility *4*:365
PGE_2 *3*:119, *3*:120
Protein synthesis (noncollagen) (NCP)
MAV-2(0)-infected culture *3*:81, *3*:82, *3*:84, *3*:87, *3*:88
pycnodysostosis *2*:99, *2*:105
Protein-phospholipids (biologic calcification) *1*:149, *1*:150, *1*:151, *1*:152
Proteoglycans
articular cartilage *1*:116
bone matrix *2*:65
calcification *1*:180
fracture callus *1*:319, *1*:320, *1*:322, *1*:323, *4*:61, *4*:64, *4*:66, *4*:67
Proteolipid
Bacterionema matruchotii calcification model *1*:149, *1*:152
biologic calcification *1*:143, *1*:144, *1*:146, *1*:149
Pseudohypoparathyroidism (type II)
anticonvulsant-treated rats *4*:273, *4*:274
growth changes 4272, *4*:273
PTH *4*:362
Pseudouridine excretion *3*:260
PTH, see Parathyroid hormone
Pycnodysostosis *2*:99, *2*:101, *2*:103, *2*:104
Pyrophosphtase activity
extracellular vesicles *1*:186, *1*:189, *1*:190
osteosarcoma matrix vesicles *1*:232
Pyrophosphate *3*:279, *3*:280

Radiation chimeras *3*:131, *3*:132
Radiocalcium absorption test *2*:233, *2*:234, *2*:236, *2*:237
Radioimmunoassay (RIA) *1*:263, *1*:264, *1*:265, *1*:266
Radioimmunoassay (RIA) development *4*:329, *4*:330, *4*:331, *4*:332
Radioiodination (PTH) *2*:25, *2*:28, *2*:29
Radiology, see also Microradiography; Microradioscopy technique
Paget's disease *3*:244, *3*:253
Reflex sympathetic dystrophy syndrome, see Sudek's atrophy
Ranal failure, see also Uremia
cortical remodeling sites *4*:353, *4*:354, *4*:355, *4*:356, *4*:357, *4*:358
hypercalcemia (malignant) *2*:191, *2*:192, *2*:195
hypercalcemic osteomalacia *4*:370
1,25-$(OH)_2$D production *4*:335, *4*:336
Renal function (hypercalcemia) *2*:153, *2*:154, *2*:155
Renal osteodystrophy, see Osteodystrophy (renal); Osteodystrophy (renal juvenile)
Renal phosphate leak (IH) *3*:39, *3*:40, *3*:41
Renal plasma membrane (PHT) *2*:25, *2*:26, *2*:27, *2*:29
Renal stones *3*:219
Renal transplants (immunosuppressive therapy)
bone formation rate *1*:45, *1*:46
osteoid maturation *1*:45, *1*:46, *1*:47
Renal tubular reabsorption (calcium) *2*:153, *2*:154, *2*:155
Rickets
matrix vesicle calcium *1*:199
mitochondrial calcium *1*:199
osteoporosis (infantile) *3*:139
vitamin D deficiency *1*:10
vitamin D metabolite *1*:9, *1*:10
Rickets (vitamin D dependency) (VDDR) *2*:17, *2*:18, *2*:20, *2*:21
Rickets (hereditary vitamin D-resistant) (VDRR) *4*:249, *2*:250, *4*:251
ROD, see Osteodystrophy (renal)

Salmon calcitonin (SCT), see Calcitonin (salmon)
Sarcoidosis (skeletal) *2*:162, *3*:171, *3*:172
Scapular (Paget's disease) *3*:250, *3*:252
Scorbutus (experimental) *1*:205, see also Cartilage (scorbutic)
Serum . . . see . . . (serum)
Sialic acid content (fracture callus matrix) *4*:61, *4*:65, *4*:66, *4*:67

Skeletal abnormalities (simulated weightlessness) *4*:347, *4*:349, *4*:350, *4*:351
Skeletal alterations (osteoporosis) *4*:69, *4*:73
Skeletal blood flow. see Bone blood flow
Skeletal development (TPTX rats) *2*:257, *2*:258, *2*:259
Skeletal envelopes (IO) *4*:285, *4*:286
Skeletal intermediary organization (IO) *4*:281, *4*:282, *4*:288
  ex-vivo studies *4*:287, *4*:288
  lower level *4*:282, *4*:283
  MCN phenomena *4*:282, *4*:283
  middle level *4*:283, *4*:284
  regular *4*:286
  temporal coherence *4*:287
  upper level *4*:284, *4*:285
Skeletal lesions (MM) *4*:164, *4*:165, *4*:166, *4*:167
Skeletal metabolic activity
  bone scan *3*:243, *3*:249, *3*:250, *3*:253
  sex hormone effect *4*:362
Skeletal metastases (breast cancer) *2*:199, *2*:200, *2*:201, *2*:202
Skeletal physiology *4*:281
  atomistic concepts *4*:281, *4*:288
  quantum concepts *4*:281, *4*:282, *4*:283, *4*:286, *4*:287, *4*:288
Skeletal sarcoidosis *2*:162, *3*:171, *3*:172, *3*:173
Skeletal tissue ultrastructure *2*:267, *2*:268, *2*:276, *2*:278
Skeleton . . . see also Bone histomorphometry
Skeleton (EHDP effects) *3*:289, *3*:290, *3*:291, *3*:292, *3*:293, *3*:295, *3*:296, *3*:300
Skin (calciphylaxis) *1*:219, *1*:225
Sodium etidronate. see EHDP
Sodium fluoride. see also Fluoride *2*:233, *3*:224
Sodium salicylate treatment *4*:367
Sodium valproate (SV) therapy *4*:273, *4*:274
Somatomedin (serum) *2*:101, *2*:103
Spinal cord dysfunction (Paget's disease)
  drug treatment *3*:331, *3*:332, *3*:333
  lesions *3*:327
  neurological improvement *3*:334
  surgical treatment *3*:332
Spinal cord injury (heterotopic ossification) *3*:337, *3*:338, *3*:339, *3*:340, *3*:341
Spleen cell infusion (osteopetrotic mice) *3*:131, *3*:132
Spleen cell transfer (osteopetrosis) *3*:107, *3*:108, *3*:110, *3*:311
Spondylosis *3*:240
Stereology
  MWT *4*:113, *4*:114, *4*:115, *4*:116, *4*:117, *4*:118
  trabecular bone *4*:291, *4*:292
Steroid therapy. see also glucocorticoids
  hypercalcemia (malignant) *2*:192, *2*:194, *2*:195
  renal failure *2*:192
  reversibility *1*:306, *1*:307
Strain
  bone architecture *4*:221, *4*:224, *4*:218
  bone modeling *4*:218, *4*:219, *4*:221, *4*:224, *4*:225, *4*:226
Stress *4*:220, *4*:228
Sucrose density gradient centrifugation *3*:209, *3*:213
Sudek's atrophy *4*:305
  bone lesions *4*:308, *4*:309, *4*:310
  bone modifications *4*:306, *4*:307, *4*:308
  vascular signs *4*:306, *4*:309, *4*:310
Sulfur content (mineralization) *4*:211, *4*:212, *4*:213, *4*:214, *4*:215
Surgery. see also Arthroplasty
  Paget's disease *3*:270, *3*:271, *3*:275, *3*:276
  spinal cord dysfunction *3*:332

TB. see Trabecular bone
TBD. see Total bone density
TBV. see Trabecular bone volume
Tetracycline (osteoblast metabolism) *3*:51, *3*:52, *3*:53, *3*:54
Tetracycline labeling *1*:45, *3*:53, *3*:54, *4*:356, *4*:357
Tetracycline labeling (double)
  bone histomorphometry *4*:232, *4*:233
  label escape error model *4*:237, *4*:238, *4*:239, *4*:241
Tetramisole (calcification *in vitro*) *3*:63, *3*:64, *3*:65
Thymus (osteopetrosis) *3*:91, *3*:94, *3*:95, *3*:97
Thyroparathyroidectomy (TPTX rats)
  bone growth *4*:270, *4*:271, *4*:272, *4*:274
  PTE metabolism *3*:313, *3*:314, *3*:315, *3*:316, *3*:317
  1,25-$(OH)_2D$ production *4*:334, *4*:335
Thyroxine *2*:181
Tibial diaphyses *4*:349, *4*:351
Tidemark (human articular cartilage) *1*:115, *1*:116, *1*:117, *1*:118
Tooth eruption (osteopetrotic *ia* rats) *3*:107, *3*:108, *3*:110, *3*:111, *4*:266, *4*:267
Toothless (*tl*) rats *3*:92, *3*:94, *3*:95, *3*:96, *3*:97
Total body calcium (IVNAA) *4*:169, *4*:170, *4*:172
Total bone density (TBD) *1*:35, *1*:36, *1*:37, *1*:38
Total bone mass (osteoporosis) *2*:108, *2*:109
TPTX. see Thyroparathyroidectomy
Trabecular bone density (inter-/intra-individual variance) *3*:187, *3*:188, *3*:189
Trabecular bone mass (osteoporosis therapy) *1*:308, *2*:108, *2*:109
Trabecular bone packets (MWT) *3*:181, *3*:182, *3*:184
Trabecular bone remodeling
  anticonvulsant therapy *2*:79, *2*:80, *4*:18, *4*:183, *4*:184
  hyperthyroid patients *3*:182, *3*:183, *3*:184
  hypothyroid patients *3*:182, *3*:183, *3*:184
  jejuno-ileal bypass *2*:77, *2*:79, *2*:80
  thyroid effect *3*:181
Trabecular bone surface *3*:53, *4*:235, *4*:300, *4*:301
Trabecular bone thickness
  lamellar *4*:291, *4*:293, *4*:294
  mean wall *3*:181, *3*:182, *3*:183, *3*:184, *4*:113, *4*:114, *4*:115, *4*:116, *4*:117, *4*:118
Trabecular bone volume (TBV)
  corticosteroid-treated patients *1*:304, *1*:305, *1*:308
  femoral neck fracture *4*:85, *4*:87, *4*:90, *4*:91
  mineralized bone *4*:232, *4*:233, *4*:234
  osteoporosis *1*:35, *1*:36, *1*:37, *1*:38
Trace elements (Paget's disease) *4*:243, *4*:244, *4*:245
1,24,25-Trihydroxyvitamin D_3. see 1,24,25-$(OH)_3D_3$
Tumors
  hypercalcemia *2*:173, *1*:174, *2*:175
  Paget's disease *3*:276, *3*:278

  Ultramicroincineration *1*:105, *1*:107
  Uremia
  APase (plasma) *4*:298, *4*:299, *4*:300
  bone histomorphometry *1*:39, *1*:40, *1*:41, *1*:43
  bone resorption *4*:299, *4*:302
  bone turnover *4*:300, *4*:301
  hydroxyproline (plasma) *4*:297, *4*:298, *4*:299, *4*:300, *4*:301, *4*:302
  hyperparathyroidism *3*:191, *3*:196, *3*:197
  vitamin D therapy *4*:297, *4*:299, *4*:301, *4*:302

Uremia (chronic) bone cell kinetics *3*:191, *3*:192, *3*:193, *3*:196
Urinary amino acids (OI) *1*:299, *1*:300, *1*:301
Urinary calcium stone disease *4*:368, *4*:370, *4*:371
Urinary excretion *1*:24, *1*:27, *1*:28
Urinary hydroxyproline (Paget's disease)
  Cl_2MDP therapy *4*:325, *4*:326
  EHDP therapy *3*:301, *3*:302, *3*:303, *3*:304
  HCT therapy *2*:87, *2*:88
Uronate concentrations (fracture callus matrix) *4*:61, *4*:62, *4*:65, *4*:66, *4*:67

Vascular disorders. see Sudek's atrophy
VDDR. see Vitamin D-dependency rickets
VDRR. see Vitamin D-resistant rickets
Vertebra (bone modeling) *4*:221, *4*:222
Vertebral bodies (Paget's disease) *3*:327, *3*:328
Vitamin A (bone resorption activation) *2*:181
Vitamin C deficiency (scorbutus)
  collagen synthesis *1*:205, *1*:209
  scorbutic cartilage *1*:205, *1*:207, *1*:208, *1*:209, *1*:210
Vitamin D
  bone formation *1*:8
  bone mineralization *1*:7, *1*:9
  bone resorption *1*:8
  depletion *4*:269, *4*:273
  femoral neck fractures *4*:85, *4*:88, *4*:89, *4*:91
  fluoride-calcium-dihydrotachysterol Ca *4*:31, *4*:32, *4*:33, *4*:34, *4*:35, *4*:36
  hyperabsorption hypercalcemia *1*:288, *1*:289
  mineral deposits *2*:119
  renal function *1*:9
Vitamin D binding protein
  human serum *3*:43, *3*:44, *3*:45
  urine *4*:12, *4*:13
Vitamin D deficiency. see also Vitamin D-dependency rickets
  aminoaciduria *2*:86
  anticonvulsant therapy *2*:81, *3*:17, *3*:18, *3*:20, *3*:21
  jejuno-ileal bypass *2*:81
  osteomalacia *1*:10
  rickets *1*:10
Vitamin D derivatives (synthetic) *1*:23, *1*:24, *1*:25, *1*:26, *1*:27, *1*:28
Vitamin D intoxication (hypercalcemia) *2*:162
Vitamin D metabolism
  anticonvulsant therapy *2*:77, *3*:17, *3*:18, *3*:20, *3*:21
  bone remodeling *4*:17, *4*:19, *4*:20, *4*:22
  calcium transport *2*:251, *2*:252, *2*:253, *2*:254
  glucocorticosteroids *2*:203
  hypercalcitoninemia *4*:17, *4*:19, *4*:20, *4*:21, *4*:22
  jejuno ileal bypass *2*:77, *2*:80, *2*:81
  metabolic bone disease *3*:165, *1*:166, *3*:168, *3*:169
  nephrotic syndrome *4*:7, *4*:11, *4*:12, *4*:13, *4*:361
  renal osteodystrophy *4*:336
Vitamin D metabolite assay *2*:164
Vitamin D metabolite therapy
  ROD (dialysis) *2*:217, *2*:218, *2*:219, *2*:220, *2*:221
  uremia (bone resorption) *4*:297, *2*:299, *4*:301, *4*:302
Vitamin D metabolites *1*:8
  bone resorption activation *2*:181
  epileptic patients *3*:17, *3*:18, *3*:20, *3*:21
  hypercalcitoninemia (MCT) *4*:17, *4*:19
  ROD *2*:217, *2*:218, *2*:219, *2*:220
Vitamin D sterols *2*:11, *2*:12, *2*:14
Vitamin D therapy
  osteodystrophy *4*:25, *4*:26, *4*:28, *4*:29
  pycnodysostosis *2*:100, *2*:105
Vitamin D_2. see also dihydroxycholecalciferol; Dihydroxyvitamin D_2

Vitamin D_2 (cont.)
anticonvulsant therapy *2*:85, *2*:86
intenance hemodialysis *1*:19, *1*:20
plasma concentrations *1*:16, *1*:17
Vitamin D_3: see Hydroxyvitamin D_3; Trihydroxyvitamin D_3
Vitamin D_3 metabolites *in vitro* *4*:138, *4*:140
calcium distribution *4*:135, *4*:136
urinary/plasma *4*:7, *4*:11, *4*:12, *4*:13
Vitamin D_3 therapy (anticonvulsant osteomalacia) *2*:83, *2*:85
Vitamin D-dependency rickets (VDDR) *1*:10
ROD *2*:17, *2*:18, *2*:20, *1*:21
Vitamin D-resistant rickets (VDRR) *3*:31, *3*:32, *3*:35, *3*:36
adult hereditary *3*:159, *3*:160, *3*:162, *4*:249, *4*:250, *4*:251
hypophosphatemic *3*:31, *3*:32, *3*:35, *3*:36, *4*:249
inorganic phosphate levels *4*:363
Pi + 1,25-$(OH)_2D_3$ therapy *3*:63, *3*:159, *3*:160, *3*:162, *3*:163

Weightlessness (simulated)
skeletal abnormalities/recovery *4*:347, *4*:349, *4*:350, *4*:351
skeletal changes *4*:69, *4*:71, *4*:73, *4*:74
Whewellite crystals (growing bone) *4*:49, *4*:50, *4*:51, *4*:53, *4*:55, *4*:58

X-rays (Paget's disease) *3*:243, *3*:244
X-ray microanalysis (mineralization) *4*:211, *4*:212, *4*:214, *4*:215

^{3}H-1,25-$(OH)_2$ metabolism *4*:206, *4*:207
^{3}H-24,25-$(OH)_2D_3$ metabolism *4*:206, *4*:207
^{3}H-25 HD_3 metabolism
GH treatment *2*:251, *2*:252, *2*:253, *2*:254
PTE-treated TPTX rats *1*:313, *1*:316
1α$(OH)D_3$
bone turnover *4*:297, *4*:299, *4*:301
calcium transport *1*:29, *1*:30, *1*:32
dialysis osteodystrophy *4*:25, *4*:28, *4*:29
hemodialysis hyperparathyroidism *1*:15, *1*:16, *1*:17, *1*:18, *1*:19, *1*:20
hemodialysis maintenance *1*:16, *1*:19, *1*:20
hyperparathyroidism (children) *1*:15, *1*:16, *1*:17, *1*:18, *1*:19, *1*:20
1α$(OH)D_3$ (cont.)
plasma concentrations *1*:16, *1*:17
ROD *2*:217, *2*:218, *2*:219, *2*:220
25-OHD
anticonvulsant therapy *3*:17, *3*:18, *3*:20, *3*:21
femoral neck fractures *4*:85, *4*:88, *4*:89, *4*:91
hypercalcitoninemia (MCT) *4*:17, *4*:19, *4*:21
osteomalacia *3*:165, *3*:169
plasma concentrations *1*:17, *4*:273
vitamin D sterol binding protein *3*:43, *3*:44, *3*:45
24,25-$(OH)_2D_3$ *3*:156, *3*:157
25-OHD_3 *2*:11, *2*:14
bone mineralization *1*:10, *1*:11
calcium transport *2*:251, *2*:252, *2*:253, *2*:254
corticosteroids *1*:303, *1*:308
dialysis osteodystrophy *4*:25, *4*:28, *4*:29
metabolism *1*:25, *1*:313, *1*:316
nephrotic syndrome *4*:7, *4*:11, *4*:12, *4*:13
renal tubular resorption *1*:9, *1*:12
25-$(OH)D_3$: 1,25$(OH)_2D$ (juvenile ROD) *4*:255, *4*:256, *4*:257, *4*:258
25 OH-trans-D_3 *1*:24, *1*:26
1,25-$(OH)_2D$
anticonvulsants *3*:17, *3*:18, *3*:20, *3*:21
calcium balance *2*:145, *2*:146
calcium storage *2*:147
calcium transport *2*:143
^{45}calcium *3*:119, *3*:120
femoral neck fractures *4*:85, *4*:86, *4*:88, *4*:89, *4*:91
hypercalcitoninemia (MCT) *4*:17, *4*:19, *4*:21, *4*:22
osteomalacia *1*:10, *1*:11
plasma concentrations *4*:273
rickets *1*:9
ROD (juvenile) *4*:255, *4*:256, *4*:257, *4*:258
skeletal sarcoidosis *3*:173
synthesis *4*:126
VDRR *3*:159, *3*:160, *3*:162
1,25-$(OH)_2D_3$ *1*:8, *1*:295, *3*:157
adult hereditary VDRR *4*:249, *4*:251, *4*:252
bone mineralization *1*:12
bone resorption (ROD) *2*:223, *2*:224, *2*:225, *2*:226, *2*:227, *2*:228, *2*:229, *2*:230
bone turnover *4*:297, *4*:299, *4*:302
calcium absorption *2*:211, *2*:213, *2*:214
calcium metabolism *1*:24, *1*:25, *1*:27, *1*:28
calcium renal tubular absorption *2*:154, *2*:155
calcium transport *1*:29, *1*:30, *1*:31, *1*:32, *2*:251, *2*:252, *2*:253, *2*:254
1,25-$(OH)_3D_3$ (cont.)
cartilage growth *4*:337, *4*:338, *4*:339, *4*:344
dialysis osteodystrophy *4*:25, *4*:28
endosteal resorption *2*:223, *2*:224, *2*:225, *2*:229
hyperparathyroidism (ROD) *2*:223, *2*:229
metabolism *1*:313, *1*:316
nephron mass reduction *4*:333, *4*:334
osteoclasts *4*:201, *4*:207
osteomalacia *1*:10, *1*:11, *2*:83, *2*:85, *3*:168, *3*:169
PTH *1*:16, *1*:18, *4*:335, *4*:336
renal failure *4*:335, *4*:336
rickets *1*:9
24,25-$(OH)_2D_3$ *3*:157
1,25-$(OH)_2D_3$ plasma synthesis *2*:247, *2*:248, *2*:250
1,25-$(OH)_2D_3$ (urinary) *4*:7, *4*:11, *4*:13
24,25-$(OH)_2D$
anticonvulsant therapy *3*:17, *3*:18, *3*:20, *3*:21
bone resorption *4*:25, *4*:26, *4*:27, *4*:28, *4*:29
calcium transport *4*:135, *4*:140
femoral neck fractures *4*:85, *4*:88, *4*:89
hypercalcitoninemia *4*:17, *4*:19, *4*:21
MCT *4*:19, *4*:21
osteodystrophy *4*:25, *4*:28, *4*:29
24,25-$(OH)_2D_3$
APase *4*:301, *4*:302
bone turnover *4*:297, *4*:299, *4*:302
calcium absorption *2*:11, *2*:12, *2*:13, *2*:14
calcium metabolism *1*:24, *1*:26, *1*:27
calcium release *4*:135, *4*:140
condylar cartilage growth *4*:339
deficiency *3*:157
therapy *1*:12
25-OH-D (plasma) *3*:156, *3*:157
24,25-$(OH)_2D_3$ (plasma)
nephrotic syndrome *4*:7, *4*:11, *4*:12, *4*:13
oral administration *3*:155, *3*:156, *3*:157
24,25-$(OH)_2D_3$ (urinary) *4*:7, *4*:11, *4*:13
1,24,25-$(OH)_3D_3$
calcium absorption *1*:295, *1*:296, *1*:297
calcium metabolism *1*:24, *1*:28
25,26-$(OH)_2D_3$ (plasma) *4*:7, *4*:12, *4*:13
25,26-$(OH)_2D_3$ (urinary) *4*:7, *4*:11

Compiled by Victoria Boyle

Metab. Bone Dis. & Rel. Res. 4, xv-xxi (1983)
Printed in the USA. All rights reserved.

0221-8747/83 $3.00/0
Copyright © 1983 Pergamon Press Ltd.

Metabolic Bone Disease & Related Research

Cumulative Author Index Volumes 1-4 1978-1983

Aaron, J.E.:The Effect of Electron Microscope Procedures on the Intracellular Distribution of Mineral *4*:372, *4*:373

Abrams, J., see Haddad, J.G., et al. *3*:43

Adams, P.H., see Walker, D., *4*:631

Adarni, S., see Allgrove, J., et al. *4*:362

Aguercif, M., see Herbage, D., et al. *4*:95

Ahlgren, O., see Larsson, S-E. *4*:121

Al-Douri, S.M.J., see Johnson, D.R. *4*:263

Alexandre, C., Meunier, P.J., Edouard, C., Khairi, R.A., Johnston, C.C.:Effects of Ethane-1 Hydroxy-1, Diphosphonate (5 mg/kg/day dose) on Quantitative Bone Histology in Paget's Disease of Bone *3*:309

Alexandre, C., see Chapuy, M.C., et al. *2*:93

Ali, S.Y., Wisby, A., Gray, J.C.:Electron Probe Analysis of Cryosections of Epiphyseal Cartilage *1*:97

Allam, B.F., see Fogelman, I., et al. *4*:370

Allen, T.D., Testa, N.G., Onions, D., Jarret, O.:Time-Lapsed Video Observations on the In Vitro Behavior of Putative Osteoclasts Generated from Feline Bone Marrow Cultures *4*:372

Allgrove, J., Adarni, S., Jayaweera, P., O'Riordan, J.L.H.:Biologically Active Parathyroid Hormone in Pseudohypoparathyroidism *4*:362

Aloia, J.F., Yeh, J.K.:Growth Hormone and Intestinal Calcium Transport in the Rat *2*:251

Aloia, J.F., see Yeh, J.K. *3*:47

Althoff, H., see Höhling, H.J., et al. *1*:109

Althuis, A.L., see Lips, P., et al. *4*:85

Altman, A.J., Bandelin, J.G., Dominguez, J.H., Mundy, G.R.:Differentiation of Isolated Calvarial Cells into a Mature Heterogenous Bone Cell Population in Culture *1*:75

Anderson, C., Danylchuk, K.D., DeLuca, H.F.:An Alteration in the Plasma Levels of 1,25 dihydroxycholecalciferol Is Not Responsible for the Bone Lesion in Chronic Cadmium Exposure in Dogs *2*:247

Anderson, D.C., see Braidman, I.P., *4*:367, *4*:368

Anderson H.c.:Introduction to the Second Conference on Matrix Vesicle Calcification *1*:83

Anderson, H.C., Hsu, H.H.T.:A New Method to Measure Calcium Accumulation by Matrix Vesicles in Slices of Rachitic Growth Plate Cartilage *1*:193

Anderson, H.C., see Cecil, R.N.A., *1*:89

Anderson, H.C., see Fortuna, R., et al. *1*:161

Anderson, H.C., see Hsu, H.H.T., et al. *1*:169

Argemi, B., see Rasmussen, H., et al. *2*:107

Arlet, J., see Bouteiller, G., et al. *4*:313

Arlot, M., see Reeve, J., et al. *3*:23

Arnaud, C., see Reeves, J., et al. *3*:135

Ashton, B.A., Owen, M.E., Eagelsom, C.C., Parsons, J.A.:Inhibitory Action of PTH on the Differentiation of Osteogenic Precursor Cells *4*:368

Atkin, I., Ornoy, A.:Transplancental Effects of Cortisone Acetate on Calcification and Ossification of Long Bones in Mice *3*:199

Atkinson, P.J., Hallsworth, A.S.:Spatial Structure in Cortical Bone *4*:368

Atkinson, P.J., see Robinson, C., et al. *4*:372

Auquier, L., see Rasmussen, H., et al. *2*:107

Avramides, A., see Kraszeski, J.L., et al. *3*:9

Bab, I., see Deutsch, D., et al. *3*:209

Bab, I., see Sela, J., et al. *4*:129

Bab, I.A., see Muhlrad, A., et al. *1*:227

Bab, I.A., see Sela, J., et al. *1*:185

Balsan, S., Gueris, J., Levy, D., Garabedian, M., Guillozo, H., Broyer, M.:Suppressive Effect of 1α-hyroxyvitamin D_3 on the Hyperparathyroidism of Children on Maintenance Hemodialysis *1*:15

Balsan, S., see Lambrey, G., et al. *4*:25

Balsan, S., see Plachot, J.J., et al. *4*:135

Bandelin, J.G., see Altman, A.J., et al. *1*:75

Banes, A.J., Mechanic, G.L.:Collagen and Noncollagen Protein Synthesis in Chick Limb Bud Cells Infected with a Virus that Causes Osteoblastoma *3*:81

Banes, A.J., see Boyde, A., et al. *1*:235

Banks, L., see Evans, I.M.A., et al. *2*:87

Barckhaus, R.H., see Höhling, H.J., et al. *1*:109

Barden, H.S., Mazess, R.B., Chesney, R.W., Rose, P.G., Chun, R.:Bone Status of Children Receiving Anticonvulsant Therapy *4*:43

Barker, D.J.P.:The Epidemiology of Paget's Disease *3*:231

Barker, D.J.P., Chamberlain, A.T., Detheridge, F.M., Gardner, M.J., Guyer, P.B.:Low Lead Levels in Pagetoid Bone *4*:243

Baron, R., see Canalis, E., et al. *2*:99

Baron, R., see Goldsmith, R.S., et al. *1*:3

Barrett, G.D., see Care, A.D., et al. *4*:371

Barrett, P.Q., Teitelbaum, A.P., Neuman, W.F.:The Heterogeneity of Radioiodinated Parathyroid Hormone in Rat Plasma *1*:263

Bartlett, M., see Cundy, T., et al. *1*:295, *4*:297

Basle, M., see Rebel, A., et al. *3*:235

Basle, M.F., Rebel, A., Renier, J.C.:Bone Tissue in Reflex Sympathetic Dystrophy Syndrome — Sudek's Atrophy:Structural and Ultrastructural Studies *4*:305

Bataille, R., Sany, J.:Clinical Evaluation of Myeloma Osteoclastic Bone Lesions:II. Induced Hypocalcemia Test Using Salmon *4*:39

Baud, C.A., Boivin, G.:Modifications of the Perilacunar Walls Resulting from the Effect of Fluoride on Osteocytic Activity *1*:49

Baylink, D.J., see Evans, R.A., et al. *2*:39

Baylink, D.J., see Howard, G.A., et al. *2*:131

Baylink, D.J., see Ivey, J.L., et al. *3*:3, *3*:39

Baylink, D.J., see Liu, C.C., et al. *1*:269, *4*:201

Baylink, D.J., see Rader, J.I., et al. *1*:313

Beard, D.J., Douglas, D.L., Paterson, A., Cameron, E.C., Kanis, J.A., Woodhead, J.S., Russell, R.G.G.:The Use of Dichloromethylene Diphosphonate (Cl_2MDP) to Evaluate the Skeletal and Renal Actions of PTH in Man *4*:364

Beard, D.J., see Douglas, D.L., et al. *3*:327

Beard, D.J., see Russell, R.G.G., et al. *3*:255

Beastall, G.H., see Fogelman, I., et al. *4*:370

Bernat, M., see Reeve, J., et al. *3*:23

Bessent, R.G., see Fogelman, I. et al. *4*:362

Best, J.J.K., see Samuel, A.W., et al. *4*:362

Betts, F., see Posner, A.S., et al. *1*:179

Bevan, J.A., see Flora, L., et al. *3*:289

Bielakoff, J., see de Vernejoul, M.C., et al. *3*:175

Bijvoet, O.L.M., Hosking, D.J., Frijlink, W.B., Te Velde, J., Vellenga, C.J.L.R.:Treatment of Paget's Disease with Combined Calcitonin and Diphosponate (EHDP) *1*:251

Bijvoet, O.L.M., see Reeve, J., et al. *2*:233

Bijovoet, O.L.M., see Vellenga, C.J.L.R., et al. *4*:103

Bishop, M., see Cundy, T., et al. *4*:297

Blanco, L., see Howell, D.S., et al. *1*:155

Blasco, A., see Bouteiller, G., et al. *2*:123, *4*:313

Block, M., see Reeves, J., et al. *3*:135

Blumenthal, N.C., see Posner, A.S., et al. *1*:179

Boivin, G., see Baud, C.A. *1*:49

Bonjour, J-P., Rizzoli, R., Hugi, K., Haldimann, B., Fleisch, H.:Effect of Synthetic Vitamin D Derivatives on Calcium and Phosphate Metabolism in Intact Vitamin D-Replete Rats *1*:23

Bonucci, E.:Matrix Vesicle Formation in Cartilage of Scorbutic Guinea Pigs:Electron Microscope Study of Serieal Sections *1*:205

Bordier, P., see Rasmussen, H., *1*:7

Bordier, P., see Rasmussen, H., et al. *2*:107

Borg, T.K., see Wuthier, R.E., et al. *1*:25

Borsali, F., see Herbage, D., et al. *4*:95

Boskey, A.L.:The Role of Calcium-Phospholipid-Phosphate Complexes in Tissue Mineralization *1*:137

Boskey, A.L., Bullough, P.G., Posner, A.S.:Calcium-Acidic Phospholipid-Phosphate Complexes in Diseased and Normal Human Bone *4*:151

Boskey, A.L., see Lane, J.M., et al. *1*:319, *4*:61

Boskey, A.L., see Warman, M. *4*:319
Bottemiller, B.L., see Howard, G.A., et al. *2*:131
Bouteiller, G., Arlet, J., Blasco, A., Vigoni, F., Elefteriou, A.: Is Osteonecrosis of the Femoral Head Avascular? Bone Blood Flow Measurements After Long-term Treatment with Corticosteroids *4*:313
Bouteiller, G., Blasco, A., Decamps, J-L., Vigoni, F., Pradere, J., Rami, J., Puel, P., Regis, H.: Use of Labeled Microspheres for Simultaneous Determination of Total and Regional Blood Flows in Canine Femur *2*:123
Boyan-Salyers, B., see Vogel, J.J., et al. *1*:149
Boyan-Salyers, B.D., Vogel, J.J., Riggan, L.J., Summers, F., Howell, R.E.: Application of Microbial Model to Bilogic Calcification *1*:143
Boyce, B.F., courpron, P., Meunier, P.J.: Amount of Bone in Osteoporosis and Physiological Senile Osteopenia:Comparison of Two Histomorphometric Parameters *1*:35
Boyce, B.F., Elder, H.Y., Fell, G.S., Ferguson, A., Boyle, I.T., Junor, B.J.R.: Hypercalcemic Osteomalacia:A Complication of Aluminum Toxicity in Chronic Renal Failure *4*:370
Boyce, B.F., see Fogelman, I., et al., *4*:373
Boyce, B.F., see Smith, M.L., et al. *4*:373
Boyde, A., Banes, A.J., Dillaman, R.M., Mechanic, G.L.:A Morphological Study of an Avian Bone Disorder Caused by Myeloblastosis-associated Virus *1*:235
Boyde, A., Jones, S.J., Howell, P.G.T., Eoss, H.F.:Sterephotogrammetric SEM Characterization of Resorption Lacunae *4*:372
Boyde, A., see Jones, S.J., et al. *4*:367
Boyle, I.T., Fogelman, I.:Glucocorticoids and Oestrogens in the Management of Hypercalcemia *2*:203
Boyle, I.T., see Boyce, B.F., et al. *4*:370
Boyle, I.T., see Smith, M.L., et al. *4*:373
Bradley, J., see Kusakabe, A., et al. *4*:367
Braidman, I.P., Anderson, D.C.:Studies on Separated Fetal and Rat Bone Cell Populations:A New View of PTH-Induced Bone Resorption *4*:367, *4*:368
Bressot, C., Meunier, P.J., Chapuy, M.C., Lejeune, E., Edouard, C., Darby, A.J.:Histomorphometric Profile, Pathophysiology and Reversibility of Corticosteroid-induced Osteoporosis *1*:303
Briancon, D., see Delmas, P.D., et al. *4*:163
Brickman, A.S., see Llach, F., et al. *2*:11
Brighton, C.T., Hunt, R.M.:Electron Microscopic Pyroantimonate Studies of Matrix Vesicles and Mitochondria in the Rachitic Growth Plate *1*:199
Brown, B.L., see Coulton, L.A., et al. *4*:369
Brown, D.M., see Teitelbaum, S.L., et al. *3*:99
Broyer, M., see Balsan, S., et al. *1*:15
Buffee, D., see Milhaud, G., et al. *3*:91
Buffevant, C., see Herbage, D., et al. *4*:95
Bullough, P.G., see Boskey, A.L., et al. *4*:151
Bullough, P.G., see Dmitrovsky, E., et al. *1*:115
Bullough, P.G., see Kinnett, J.G. *1*:299
Bulman, R.A., Griffin, R.J.:In Vitro Uptake of Actinides by a Cacifying Lipoprotein *2*:281
Bydder, G.M., see Hesp, R., et al. *4*:169

Caillen, C., see Lambrey, G., et al. *4*:25
Cameron, E.C., see Beard, D.J., et al. *4*:364
Cameron, E.C., see Russell, R.G.G., et al. *3*:255
Campbell, M.M., see Vogel, J.J., et al. *1*:149
Canalis, E., Reardon, G.E., Baron, R., Raisz, L.G.:Dynamic Bone Morphometry and Studies on the Effects of Serum on Bone Metabolism In Vitro in a Case of Pycnodysostosis *2*:99
Canfield, R.S., see Siris, E.S., et al. *3*:301
Care, A.D., Ross, R., Barrell, G.D., Muir, P., Ross, A., Sykes, A.R.:Studies on Calcium Homeostasis and Antler Growth in the Stag (*cervus elaphus*) *4*:371
Carr, D., see Fogelman, I., et al. *3*:243
Carson, F.L., see Matthews, J.L., et al. *1*:219
Carty, R.P., see Fortuna, R., et al. *1*:161
Casco, C., see Mautalen, C.A., et al. *4*:187
Caulin, F., see Rasmussen, H., et al. *2*:107
Cecil, R.N.A., Anderson, H.C.:Freeze-fracture Studies of Matrix Vesicle Calcification in Epiphyseal Growth Plate *1*:89
Cecil, R.N.A., see Hsu, H.H., et al. *1*:169
Challa, A., see Noorwali, A., et al. *4*:363
Chamberlain, A.T., see Barker, D.J.P., et al. *4*:243
Chambers, T.J., Magnus, C.J.:Calcitonin Alters Behavior of Isolated Osteoblasts *4*:367
Chapuy, M.C., Charhon, S.A., Meunier, P.J.:Sustained Biochemical Effect of Short Treatment of Paget's Disease of Bone with Dichloromethylene Diphosphonate *4*:325
Chapuy, M.C., Meunier, P.J., Alexandre, C.:Comparison of the Acute Effects of Human and Salmon Calcitonins in Pagetic Patients:Relation with Plasma Calcitonin Levels *2*:93
Chapuy, M.C., see Bressot, C., et al. *1*:303
Chapuy, M.C., see Delmas, P.D., et al. *4*:163
Charon, S., see Delmas, P.D., et al. *4*:163
Charon, S., see Reeve, J., et al. *3*:23
Charon, S.A., see Chapuy, M.C., et al. *4*:325
Checkley, D.R., see Samuel, A.W., et al. *4*:362
Chesney, R.W., see Barden, H.S., et al. *4*:43
Christensen, C.K., Lund, B., Lund, B.J., Sørensen, O.H., Nielsen, H.E., Mosekilde, L.:Reduced 1,25-Dihydroxyvitamin D and 24,25-Dihydroxyvitamin D in Epileptic Patients Receiving Combined Anticonvulsant Therapy *3*:17
Chun, R., see Barden, H.S., et al. *4*:43
Clemens, T.L., see Compston, J.E., et al. *3*:165
Cloyd, G.G., see Flora, L., et al. *3*:289
Coburn, J.W., see Llach, F., et al. *2*:11
Coccia, P.F., see Teitelbaum, S.L., et al. *3*:99
Cohn, D.V., see Kent, G.N. *3*:151
Compston, J.E., Merrett, A.L., Ledger, J.E., Creamer, B.:Fecal Tritium Excretion of Intravenously Administered (^{3}H) 25-Hyroxyvitamin D_3 in Normal Subjects and Patients with Intestinal Malabsorption *4*:362
Compston, J.E., Vedi, S., Merrett, A.L., Clemens, T.L., O'Riordan, J.L.H., Woodhead, J.S.:Privational and Malabsorption Metabolic Bone Disease:Plasma Vitamin D Metabolite Concentrations and Their Relationship to Quantitative Bone Histology *3*:165
Compston, J.E., see Vedi, S., et al. *4*:231
Coombes, R.C., Dady, P., Parsons, C., Powles, T.J.:Mithramycin Therapy: An Adjunct to Conventional Treatment of Hypercalcaemia and Bone Metastases in Breast Cancer *2*:199
Coulton, L.A., Tomlinson, S., Brown, B.L.:Calcium, Calmodulin, and Alkaline Phosphatase Activity in an Osteoblast-like Tumor Cell Line *4*:369
Cournot-Witmer, G., see Plachot, J.J., et al. *4*:135
Courpron, P., see Boyce, B.F., et al. *1*:35
Cox, K.A., see Holtrop, M.E., et al. *3*:123
Creamer, B., see Compston, J.E., et al. *4*:362
Cuenoud, M.L., see Schneider, G.B., et al. *1*:335
Cundy, T., Bartlett, M., Bishop, M., Earnshaw, M. Smith, R., Kanis, J.A.:Plasma Hydroxyproline in Uremia:Relationships with Histologic and Biochemical Indices of Bone Turnover *4*:297
Cundy, T., Kanis, J.A., Paton, S., Smith, R., Warner, G.T., Bartlett, M., Russell, R.G.G.:The Biological Effects of 1, 24, 25-Trihydroxyvitamin D_3 in Man *1*:295
Cundy, T., see Kanis, J.S., et al. *2*:151, *3*:155
Curci, G., see Mazza, A., et al. *2*:64

Dady, P., see Coombes, R.C., et al. *2*:199
Danylchuk, K.D., see Anderson, C., et al. *2*:247
Darby, A., see Parsons, V., et al. *2*:191
Darby, A.J., see Bressot, C., et al. *1*:303
Debman, J., see Hruska, K.A., et al. *1*:39
Decamps, J-L., see Bouteiller, G., et al. *2*:123
de Fremont, J.F., see Lambrey, G., et al. *4*:25
de Fremont, J.F., see Sebert, J.L., et al. *2*:217
Delmas, P.D., Charhon, S., Chapuy, M.C., Vignon, E., Briancon, D., Edouard, D., Meunier, P.J.:Long-term Effects of Dichloromethylene Diphosphonate (Cl_2MDP) on Skeletal Lesions in Multiple Myeloma *4*:163
DeLuca, H.F., see Anderson, D., et al. *2*:247
DeLuca, H.F., see Horst R.L., et al. *1*:29
Delvin, E.E., see Glorieux, F.H., et al. *3*:143
Deol, M.S., see Sela, J., et al. *4*:129
DeOreo, P.B., see Lambert, P.W., et al. *4*:7
Detheridge, F.M., see Barker, D.J.P., et al. *4*:243
Deutsch, D., Bab, I., Muhlrad, A., Sela, J.:Purification and Further Characterization of Isolated Matrix Vesicles from Rat Alveolar Bone *3*:209
de Vernejoul, M.C., Kuntz, D., Miravet, L., Gueris, J., Bielakoff, J., Ryckewaert, A.:Bone Histomorphometry in Hemodialysed Patients *3*:175
de Wardener, H.E., see Eastwood, J.B., et al. *2*:83
Dillaman, R.M., see Boyde, A., et al. *1*:235
Dirks, O.B., see van Kesteren, R.G., et al. *4*:31
Dishe, F., see Parsons, V., et al. *2*:191
Dmitrovsky, E., Lane, L.B., Bullough, P.G.:The Characterization of the Tidemark in Human Articular Cartilage *1*:115
Dominguez, J.H., see Altman, A.J., et al. *1*:75
Doppelt, R., see Matthews, J.L., et al. *2*:113
Dougherty, W.J.:The Occurence of Amorphous Mineral Deposits in Association with the Plasma Membrane of Active Osteoblasts in Rat and Mouse Alveolar Bone *1*:119
Douglas, D.L., Kanis, J.A., Duckworth, T., Beard, D.J., Paterson, A.D., Russell, R.G.G.:Paget's Disease:Improvement of Spinal Cord Dysfunction with Diphosphonates and Calcitonin *3*:327
Douglas, D.L., see Beard, D.J., et al. *4*:364
Douglas, D.L., see Ibbotson, K.J., et al. *2*:177
Douglas, D.L., see Kanis, J.A., et al. *3*:155
Douglas, D.L., see Russell, R.G.G., et al. *3*:255
Dowsett, C., see Wilkinson, R., et al. *4*:364
Doyle, F.H., see Evans, I.M.A., et al. *2*:87
D'Souza, S.M., see Ibbotson, K.J., et al. *2*:177

du Bois, M.B., see Plachot, J.J., et al. *4*:135
Duckworth, T., see Douglas, D.L., et al. *3*:327
Duursma, S.A., see van Kesteren, R.G., et al. *4*:31
Duursma, S.A., see Visser, W.J., et al. *3*:187
Dziedzic-Goclawska, A., Ostrowski, K., Michalik, J., Stachowicz, W., Moutier, R., Toyama, K., Lamendin, H.: Decrease of the Crystallinity of Bone Mineral in Osteopetrotic Rats, *2*:33

Eagelsom, C.C., see Ashton, B.A., et al. *4*:368
Eanes, E.D., Reddi, A.H.: The Effect of Fluoride on Bone Mineral Apatite *2*:3
Earnshaw, M., see Cundy, T., et al. *4*:297
Eastwood, J.B., Phillips, M.E., de Wardener, H.E.: Effect of Vitamin D_3 (cholecalciferol) in Anticonvulsant Osteomalacia *2*:83
Eaton, B., see Lane, J.M., et al. *1*:319
Edouard, C., see Alexandre, C., et al. *3*:309
Edouard, C., see Bressot, C., et al. *1*:303
Edouard, C., see Dellmas, P.D., et al. *4*:163
Edouard, C., see Reeve, J., et al. *3*:23
Eilon, G., see Holtrop, M.E., et al. *3*:123
Eilon, G., see Mundy, G.R., et al. *2*:173
Eisinger, J.B., see Rasmussen, H., et al. *2*:107
Elder, H.Y., see Boyce, B.F., et al. *4*:370
Elefterion, A., see Bouteiller, G., et al. *4*:313
Elsasser, U., see Hesp, R., et al. *4*:169
Emmertsen, K., Melsen, F., Mosekilde, L., Lund, B.I., Lund, B.J., Sørensen, O.H., Nielsen, H.E., Sølling, H., Hansen, H.H.: Altered Vitamin D Metabolism and Bone Remodelling in Patients with Medullary Thyroid Carcinoma and Hypercalcitoninemia *4*:17
Emond, A., see Parsons, V., et al. *2*:191
Evans, I.M.A., Banks, L., Doyle, F.H., Joplin, G.F., Pennock, J., Stevenson, J.C., MacIntyre, I.: Paget's Disease of Bone: The Effect of Stopping Long Term Human Calcitonin and Recommendations for Future Treatment *2*:87
Evans, R.A., Baylink, D.J., Wergedal, J.: The Effects of Two Diphosphonates on Bone Metabolism in the Rat *2*:39
Evanson, J.M., see Kanis, J.A., et al. *3*:219

Fallon, M.D., Perry, H.M. III, Teitelbaum, S.L.: Skeletal Sarcoidosis with Osteopenia *3*:171
Farmer, J.E., see Kusakabe, A., et al. *4*:367
Fell, G.S., see Boyce, B.F., et al. *4*:370
Felluga, B., see Mazza, A., et al. *2*:65
Ferguson, A., see Boyce, B.F., et al. *4*:370
Filmon, R., see Rebel, A., et al. *3*:235
Finerman, G.A.M., Stover, S.L.: Heterotopic Ossification Following Hip Replacement of Spinal Cord Injury: Two Clinical Studies with EHDP *3*:337
Fisken, R.A., see Wilkinson, R., et al. *4*:364
Flandin, F., see Herbage, D., et al. *4*:95
Fleisch, H.: Diphosphonates: History and Mechanisms of Action *3*:279
Fleisch, H., see Bonjour, J-P., et al. *1*:23
Fleisch, H., see Gallagher, J.A., et al. *4*:369
Flora, L., Hassing, G.S., Cloyd, G.G., Bevan, J.A., Parfitt, A.M., Villanueva, A.R.: The Long-Term Skeletal Effects of EHDP in Dogs *3*:289
Fogelman, I., Bessent, R.G., Smith, L.M., Hart, D.M., Lindsay, R.: The Short-Term Evaluation of Sex-Hormone Effect on Skeletal Metabolism by 24-Hour Whole Body Retention of Diphosphonate *4*:362
Fogelman, I., Carr, D., Boyle, I.T.: The Role of Bone Scanning in Paget's Disease *3*:243
Fogelman, I., Gray, J.M.B., Gardner, M.D., Beastall, G.H., McIntosh, W.B., Allam, B.F., Boyce, B.F., Boyle, I.T., Lawson, D.H.: Do Anticonvulsant Drugs Commonly Induce Osteomalacia? *4*:370
Fogelman, I., see Boyle, I.T. *2*:203
Fogelman, I., see Smith, M.L., et al. *4*:373
Forrest, A.R.W., see Russell, R.G.G., et al. *3*:255
Fortuna, R., Anderson, H.C., Carty, R.R., Sajdera, S.W.: The Purification and Molecular Characterization of Alkaline Phosphatases from Chrondrocytes and Matrix Vesicles of Bovine Fetal Epiphyseal Cartilage *1*:161
Fournier, A. see Lambrey, G., et al. *4*:25
Fournier, A., see Sebert, J.L., et al. *2*:217
Francis, M.J.O., see Kusakabe, et al. *4*:367
Fraser, D., see Nikiforuk, G. *2*:17
Frijlink, W.B., see Bijvoet, O.L.M., et al. *1*:251
Frijlink, W.B., see Vellenga, C.J.L.R., et al. *4*:103
Fromm, G.A. see Mautalen, C.A., et al. *4*:187
Frost, H.M.: Mechanical Determinants of Bone Modeling *4*:217
Frost, H.M.: The Skeletal Intermidiary Organization *4*:281
Fu, I.Y., see Lambert, P.W., et al. *4*:7

Galasko, C.S.B., see Lacey, E., et al. *4*:364
Gallagher, J.A., Guenther, H.L., Fleisch, H.: Effect of Dichloromethylene Bisphosphonate on Collagen Synthesis in Isolated Bone Cells *4*:369
Garabedian, M., see Balsan, S., et al. *1*:15
Garabedian, M., see Lambrey, G., et al. *4*:25
Garabedian, M., see Plachot, J.J., et al. *4*:135
Gardner, D.L., see O'Connor, P., et al. *4*:365
Gardner, M.D., see Fogelman, I., et al. *4*:370
Gardner, M.J., see Barker, D.J.P., et al. *4*:243
Gay, C.V., Schraer, H., Hargest, T.E., Jr.: Ultrastructure of Matrix Vesicles and Mineral in Unfixed Embryonic Bone *1*:105
Glorieux, F.H., Pettifor, J.M., Marie, P.J., Delvin, E.E., Travers, R., Shepard, N.: Induction of Bone Resorption by Parathyroid Hormone in Congenital Malignant Osteopetrosis *3*:143
Glorieux, F.H., see Marie, P.J. *3*:31, *3*:159, *4*:249
Goldsmith, R.S., Meunier, P.J., Baron, R., Goodman, D.B.P. (Editorial) *1*:3
Golembiewski, G., see Lane, J.M., et al. *4*:61
Gonzales, D., see Mautalen, C.A., et al. *4*:187
Goodman, D.B.P., see Goldsmith, R.S., et al. *1*:3
Gordon, S., see Reeves, J., et al. *3*:135
Gore, S.T., see Wuthier, R.E., et al. *1*:125
Gray, J.C., see Ali, S.Y., et al. *1*:97
Gray, J.M.B., see Fogelman, I., et al. *4*:370
Green, J.R., see Parry, R., et al. *4*:368
Green, J.R., see Wootton, R., et al. *3*:263
Griffin, R.J., see Bulman, R.A. *2*:281
Groot, C.G.: An Electron Microscopic Examination for the Presence of Acid Groups in the Organic Matrix of Mineralization Nodules in Foetal Bone *4*:77
Groot, C.G.: Electron Microscopical X-ray Microanalysis of Mineralization Nodules and Several Other Tissue Compartments in Fetal Bone *4*:211
Gruber, H., see Liu, C-C., et al. *4*:201
Guenther, H.L., see Gallagher, J.A., et al. *4*:369
Gueris, J., see Balsan, S., et al. *1*:15
Gueris, J., see De Vernejoul, M.C., et al. *3*:175
Gueris, J., see Lambrey, G., et al. *4*:25
Gueris, J., see Rasmussen, H., et al. *2*:107
Gueris, J., see Sebert, J.L., et al. *2*:217
Guilland-Cumming, D., see Russell, R.G.G., et al. *3*:255
Guillozo, H., see Balsan, S., et al. *1*:15
Gundersen, H.J.G., see Kragstrup, J., et al. *4*:113
Guyer, P.B.: Paget's Disease of Bone: The Anatomical Distribution *3*:239
Guyer, P.B., see Barker, D.J.P., et al. *4*:243

Haddad, J.G., Abrams, J., Walgate, J.: Affinity Chromatography with 25-Hyroxycholecalciferol Ester in the Isolation of the Binding Protein for Vitamin D and Its Metabolites from Human Serum *3*:43
Haldiman, B., see Bonjour, J-P., et al. *1*:23
Hallsworth, A.S., see Atkinson, P.J. *4*:368
Halpern, S., see Plachot, J.J., et al. *4*:135
Hansen, C.T., see Raisz, L.G., et al. *3*:117
Hansen, H.H., see Emmertsen, K., et al. *4*:17
Hargest, T.E., Jr., see Gay, C.V., et al. *1*:105
Harris, M., see Robinson, P.B., et al. *4*:269
Hart, D.M., see Fogelman, I., et al. *4*:362
Harvey, J.J., see Parry, R., et al. *4*:368
Harvey, W., see Robinson, P.B., et al. *4*:269
Hassing, G.S., see Flora, L., et al. *3*:289
Haussler, M., see Reeves, J., et al. *3*:135
Heath, D.A.: The Role of Mithramycin in the Management of Paget's Disease *3*:343
Heath, D.A.: The Use of Inorganic Phosphate in the Management of Hypercalcemia *2*:213
Heath, D.A., see Wilkinson, R., et al. *4*:364
Herbage, D., Borsali, F., Buffevant, C., Flandin, F., Aguercif, M.: Composition, Cross-Linking and Thermal Stability of Bone and Skin Collagens in Patients with Osteogenesis Imperfecta *4*:95
Hesp, R., Bydder, G.M., Elsasser, U., Reeve, J., Spinks, T.J.: Regional Bone Density Measurements Compared to Total Body Calcium in Osteoporosis *4*:169
Heynen, G., see Kanis, J.A., et al. *2*:151
Höhling, H.J., Barckaus, R.H., Krefting, E.R., Quint, P., Althoff, J.: Quantitative Electron Microscopy of the Early Stages of Cartilage Mineralization *1*:109
Hollis, B.W., see Lambert, P.W., et al. *4*:7
Holtrop, M.E., Cox, K.A., Eilon, G., Simmons, H.A., Raisz, L.G.: The Ultrastructure of Osteoclasts in Microphthalmic Mice *3*:123
Holtrop, M.E., see King, G.J., et al. *1*:67
Horiuchi, N., see Kawaguchi, Y., et al. *4*:333
Horsman, A.: The Application of the Multi-wire Proportional Counter to Bone Densitometry *4*:363
Horst, R.L., DeLuca, H.F., Jorgensen, N.A.: The Effect of Age on Calcium Absorption and Accumulation of 1,25-Dihydroxyvitamin D_3 in Intestinal Mucosa of Rats *1*:29
Hosking, D.J.: Calcitonin and Diphosphonate in the Treatment of Paget's Disease of Bone *3*:317
Hosking, D.J.: Treatment of Severe Hypercalcaemia with Calcitonin *2*:207
Hosking, D.J., see Bijvoet, O.L.M., et al. *1*:251
Hosking, D.J., see Vellenga, C.J.L.R., et al. *4*:103
Howard, G.A., Bottemiller, B.L., Baylink, D.J.: Evidence for the Coupling of Bone Formation to Bone Resorption In Vitro *2*:131
Howard, G.A., see Radar, J.I., et al. *1*:313
Howell, D.S., Blanco, L., Pita, J.C., Muniz, O.: Further Characterization of a Nucleational Agent in Hypertrophic Cell Extra-Cellular Fluid *1*:155

Howell, P.J.T., see Boyde, A., et al. *4*:372
Howell, R.E., see Boyan-Salyers, B.D., et al. *1*:143
Hruska, K.A., Teitelbaum, S.L., Kopelman, R., Richardson, C.A., Miller, P., Debman, J., Martin, K., Slatopolsky, E.: The Predictability of the Histological Features of Uremic Bone Disease by Non-invasive Techniques *1*:39
Hsu, H.H.T., Cecil, R.N.A., Anderson, H.C.: Role of Adenosine Triphosphatase Phospholipids and Vesicular Structure in the Calcification of Isolated Reconstituted Matrix Vesicles *1*:169
Hsu, H.H.T., see Anderson, H.C. *1*:193
Huffer, W., see Reeves, J., et al. *3*:135
Hugi, K., see Bonjour, J-P., et al. *1*:23
Hunt, R.M., see Brighton, C.T., *1*:199
Hussain, M.N., see Kraszeski, J.L., et al. *3*:9

Ibbotson, K.J., D'Souza, S.M., Kanis, J.A., Douglas, D.L., Russell, R.G.G.: Physiological and Pharmacological Regulation of Bone Resorption *2*:177
Imamura, N., see Kawaguchi, Y., et al. *4*:333
Ivey, J.L., Baylink, D.J.: Postmenopausal Osteoporosis Proposed Roles of Defective Coupling and Estrogen Deficiency (Editorial) *3*:3
Ivey, J.L., Roos, B.A., Shen, F.H., Baylink, D.J.: Increased Immunoreactive Calcitonin in Idiopathic Hypercalciuria *3*:39

Jacobs, T.P., see Siris, E.S., et al. *3*:301
Jarret, O., see Allen, T.D., et al. *4*:372
Jayaweera, P., see Allgrove, J., et al. *4*:362
Jee, W.S.S., see Miller, S.C., *2*:239
Jee, W.S.S., see Wang, T.M., et al. *4*:193
Jee, W.S.S., see Yee, J.A. *3*:55
Johnson, D.R., Al-Douri, S.M.J.: Osteoclasts with Ruffled Borders from the Tip of the Erupting Incisors of Osteopetrotic Mice and Rats *4*:263
Johnson, N.W., see Tinkler, S.M.B., et al. *4*:365
Johnson, C.C., see Alexandre, C., et al. *3*:309
Jones, S.J., Boyde, A., Maconnachie, E.: Combined Light and Scanning Electron Microscopic Studies of Rat Calvarial Osteoclast *4*:367
Jones, S.J., see Boyde, A., et al. *4*:372
Jongen, M.J.M., see Lips, P., et al. *4*:85
Joplin, G.F., see Evans, I.M.A., et al. *2*:87
Jorgensen, N.A., see Horst, R.L., et al. *1*:29
Jovanovic, V., see Rezakovic, D., *4*:175
Julien, A., see Rasmussen, H., et al. *2*:107
Junor, B.J.R., see Boyce, B.R., et al. *4*:370
Juster, M., see Milhaud, G., et al. *3*:91

Kaetzel, D.M., see Lambert, P.W., et al. *4*:7
Kahn, A.J., Raisz, L.G.: Dedication to Donald G. Walker *3*:77
Kahn, A.J., see Krukowski, M. *2*:257
Kahn, A.J., see Teitelbaum, S.L., et al. *3*:99
Kanis, J.A.: Symposium on the Etiology and Medical Management of Hypercalcaemia (Editorial) *2*:141
Kanis, J.A., Cundy, T., Heynen, G., Russell, R.G.G.: The Pathophsiology of Hyerpercalcaemia *2*:151
Kanis, J.A., Evanson, J.M., Russell, R.G.G.: Paget's Disease of Bone: Diagnosis and Management *3*:219
Kanis, J.A., Russell, R.G.G.: Diphosphonates and Paget's Disease of Bone (Editorial) *3*:217
Kanis, J.A., Taylor, C.M., Douglas, D.L., Cundy, T., Russell, R.G.G.: Effects of 24,25-Dihydroxyvitamibn D_3 on Its Plasma Level in Man *3*:155
Kanis, J.A., see Beard, D.J., et al. *4*:364
Kanis, J.A., see Cundy, T., et al. *1*:295, *4*:297
Kanis, J.A., see Douglas, D.L., et al. *3*:327
Kanis, J.A., see Ibbotson, K.J., et al. *2*:177
Kanis, J.A., see Noorwali, A., et al. *4*:363
Kanis, J.A., see Russell, R.G.G., et al. *3*:255
Katirtzoglou, A., see Meema, H.E., et al. *2*:223
Kawaguchi, Y., Kimura, Y., Yamamoto, M., Imamura, N., Tukui, I., Horiuchi, N., Suda, T., Ogura, Y., Oda, Y., Miyahara, T.: Graded Nephron Mass Reduction and Renal Synthesis of 1,25-Dihydroxyvitamin D_3 in the Rat *4*:333
Kawilarang-de Haas, E.W.M., see Nijweide, P.J., et al. *3*:61
Keenan, J., see Parsons, V., et al. *2*:191, *4*:363
Kent, G.N., Cohn, D.V.: Blood Levels of Calcitonin in Microthalmic (mi/mi) Osteopetrotic Mouse Cannot Account for the Resistance of Bone to This Hormone *3*:151
Khairi, R.A., see Alexandre, C., et al. *3*:309
Kim, K.M.: Matrix Vesicle Calcification of Rat Aorta in Millipore Chambers *1*:213
Kimmel, D., Ritz, W., Krempien, B., Mehls, O.: Bone Cell Kinetics and Function During Experimental Uremia *3*:191
Kimura, Y., see Kawaguchi, Y., et al. *4*:333
King, G.J., Holtrop, M.E., Raisz, L.G.: The Relation of Ultrastructural Changes in Osteoclasts to Resorption in Bone Cultures Stimulated with Parathyroid Hormone *1*:67
Kinnett, J.G., Bullough, P.G.: Urinary Amino Acids in Osteogensis Imperfecta *1*:299
Kirkham, J., see Robinson, C., et al. *4*:372
Kopelman, R., see Hruska, K.A., et al. *1*:39
Kragstrup, J., Gundersen, H.J.G., Melsen, F., Mosekilde, L.: Estimation of the Three-dimensional Wall Thickness of Completed Remodeling Sites in Iliac Trabecular Bone *4*:113
Kragstrup, J., Melsen, F., Mosekilde, L.: Effects of Thyroid Hormone(s) on Mean Wall Thickness of Trabecular Bone Packets *3*:181
Kragstrup, J., Melsen, F., Mosekilde, L.: Reduced Wall Thickness of Completed Remodeling Sites in Iliac Trabecular Bone Following Anticonvulsant Therapy *4*:181
Kragstrup, J., Melsen, F., Mosekilde, L.: Thickness of Lamellae in Normal Human Iliac Trabecular Bone *4*:291
Kraszeski, J.L., Avramides, A., Wallach, S., Hussain, M.N.: Three Adult Cases Resembling Hereditary Bone Dysplasia *3*:9
Krefting, E.R., see Höhling, H.J., et al. *1*:109
Krempien, B., Ritz, E.: Effects of Parathyroid Hormone on Osteocytes: Ultrastructural Evidence for Anisotropic Osteolysis and Involvement of the Cytoskeleton *1*:55
Krempien, B., see Kimmel, D., et al. *3*:191
Krolner, B., Nielsen, S.P.: Lumbar Spine Osteodensitometry *4*:363
Krukowski, M., Kahn, A.J.: The Role of Parathyroid Hormone in Mineral Homeostasis and Bone Modeling in Suckling Rat Pups *2*:257
Kunts, D., see de Vernejoul, M.C., et al. *3*:175
Kuntz, D., see Rasmussen, H., et al. *2*:107
Kuntz, D., see Sebert, J.L., et al. *2*:217
Kusakabe, A., Farmer, J.E., Bradley, J., Francis, M.J.O.: A Quantitative Ultrastructural Study of Rabbit Osteoclasts: Effects of In Vivo Sodium Salicylate Treatment *4*:367

Labat, M-L., see Milhaud, G., et al. *3*:91
Lacey, E., Rushton, S., Galasko, C.S.B.: The Osteolysis Due to Breast Cancer *4*:364
Lagier, R., Revell, P., Schoenboerner, A.: Calcium Oxalate Deposition in Growing Bone: Anatomical and Radiological Study in a Case of Primary Oxalosis *4*:49
Lambert, P.W., DeOreo, P.B., Fu, I.Y., Kaetzel, D.M., von Ahn, K., Hollis, B.W., Roos, B.A.: Urinary and Plasma Vitamin D_3 Metabolites in the Nephrotic Syndrome *4*:7
Lambrey, G., N'guyen, T.M., Garabedian, M., Sebert, J.L., de Fremont, J.F., Marie, P., Caillens, C., Gueris, J., Meunier, P., Balsan, S., Fournier, A.: Possible Link between Changes in Plasma 24, 25-Dihydroxyvitamin D and Healing of Bone Resorption in Dialysis Osteodystrophy *4*:25
Lambrey, G., see Sebert, J.L., et al. *2*:217
Lamendrin, H., see Dziedzic-Goclawska, A., et al. *2*:33
Lane, J.M., Boskey, A.L., Li, W.K.P., Ealon, B., Posner, A.S.: A Temporal Study of Collagen Proteoglycan, Lipid and Mineral Constituents in a Model of Encochondral Osseous Repair *1*:319
Lane, J.M., Golembiewski, G., Boskey, A.L., Posner, A.S.: Comparative Biochemical Studies of the Callus Matrix in Immobilized and Non-immobilized Fractures *4*:61
Lane, L.B., see Dmitrovsky, E., et al. *1*:115
Larsson, S-E., Ahlgren, O.: Effects of Disodium Ehtan-1-Hydroxy-1, 1-Diphosphonate (EHDP) in Adult Normal and Selectively Parathyroidectomized rats I. Effects on Plasma Calcium, Bone Tissue, and Adrenal Glands at Low or Normal Calcium Intake *4*:121
Lawson, D.H., see Fogelman, I., et al. *4*:370
Ledger, J.E., see Compston, J.E., et al. *4*:362
Lee, N.H., see Shapiro, I.M., *1*:173
Lejeune, E., see Bressot, C., et al. *1*:303
Lepatezour, A., see Rebel, A., et al. *3*:235
Levitans, S., see Silbermann, M., et al. *4*:337
Levy, D., see Balsan, S., et al. *1*:15
Lewinson, D., Silbermann, M.: Chrondrocyte Involvement in Condylar Calcification Utilizing Potassium Pyroantimonate-Osmium Tetroxide *1*:243
Lewinson, D., Silberman M.: Landmarks in Chrondrocyte Differentiation and Maturation as Envisaged by Changes in the Distribution of Calcium Complexes: an Ultrastructural Histochemical Study *4*:143
Lewinson, D., see Silbermann, M., et al. *2*:267, *3*:67
Li, W.K.P., see Lane, J.M., et al. *1*:319
Linder, J.E., see Tinkler, S.M.B., et al. *4*:365
Linder, R.E., see Wuthier, R.E., et al. *1*:125
Lindsay, R., see Fogelman, I., et al. *4*:362
Lips, P., Netelenbos, J.C., Jongen, M.J.M., van Ginkel, F.C., Althuis, A.L., van Schaik, C.L., van der Vijgh, W.J.F., Vermeiden, J.P.W., van der Meer, C.: Histomorphometic Profile and Vitamin D Status in Patients with Femoral Neck Fracture *4*:85
Litwin, I., see Milhaud, G., et al. *3*:91

Liu, C-C., Baylink, D.J., Wergedal, J.:Immobilization and Its Effect on Bone Repletion in Calcium-deficient Rats Fed a High Calcium Diet *1*:269

Liu, C-C., Rader, J.I., Gruber, H., Baylink, D.J.:Acute Reduction in Osteoclast Number During Bone Repletion *4*:201

Llach, F., Brickman, A.S., Singer, F.R., Coburn, J.W.:24,25-Digydroxy-Chocecalciferol, a Vitamin D Sterol with Qualitatively Unique Effects in Uremic Man *2*:11

Loutit, J.F., Peters, J., Marshall, M.J.:Colony Forming Units and Haematopoietic Stem Cells in Osteoclastopoiesis *3*:131

Lowes, J., see Parsons, V., et al. *4*:363

Lund, Bi., see Christensen, C.K., et al. *3*:17

Lund, Bi., see Emmertsen, K., et al. *4*:17

Lund, Bj., see Christensen, C.K., et al. *3*:17

Lund, Bj., see Emmertsen, K., et al. *4*:17

MacIntyre, I., see Evans, I.M.A., et al. *2*:87

MacIntyre, I., see Stevenson, J.C., et al. *4*:361

Maconnachie, E., see Jones, S.J., et al. *4*:367

Magnus, C.J., see Chambers, T.J. *4*:367

Makdassi, R., see Sebert, J.L., et al. *2*:217

Malkani, K., see Rebel, A., et al. *3*:235

Mallette, L.E.:Immunoreactivity of Human Parathyroid Hormone (28-48) Attempt to Develop an Assay for Intact Human Parathyroid Hormone *4*:329

Marie, P., see Lambrey, G., et al. *4*:25

Marie, P., see Rasmussen, H., et al. *2*:107

Marie, P., see Sebert, J.L., et al. *2*:217

Marie, P.J., Glorieux, F.H.:Histomorphometry in Asymptomatic Adults with Hereditry Hypophosphatemic Vitamin D-Resistant Rickets *4*:249

Marie, P.J., Glorieux, F.H.:Histomorphometric Study of Bone Remodeling in Hypophosphatemic Vitamin D-Resistant Rickets *3*:31

Marie, P.J., Glorieux, F.H.:Stimulation of Cortical Bone Mineralization and Remodeling by Phosphate and 1,25-Dihydroxyvitamin D in Vitamin D-Resistant Rickets *3*:159

Marie, P.J., see Glorieux, F.H., et al. *3*:143

Marks, S.C., Jr.:Tooth Eruption Depends on Bone Resorption:Experimental Evidence from Osteopetrotic (ia) Rats *3*:107

Marks, S.C., Jr., see Schneider, G.B., et al. *1*:335

Marotti, G.:Osteocyte Orientation in Human Lamellar Bone and Its Relevance to the Morphometry of Periosteocytic Lacunae *1*:325

Marshall, M.J., see Loutit, J.F., et al. *3*:131

Martin, J.H., see Matthews, J.L., et al. *1*:219

Martin, K., see Hruska, K.A., et al. *1*:39

Martin, T.J., Partridge, N.C.:Prostaglandins, Cancer and Bone:Pharmacological Considerations *2*:167

Martino, L.J., Seideman, B.:The Effect of Dichloromethylene Diphosphonate (Cl_2MDP) on Osteocyte Activity During Immobilization Osteoporosis in Rats *2*:261

Matthews, J.L., Martin, J.H., Carson, F.L.:Ultrastructure of Calciphylaxis in Skin *1*:219

Matthews, J.L., Talmage, R.V., Doppelt, R.:Responses of the Osteocyte Lining Cell Complex — the Bone Cell — to Calcitonin *2*:113

Matthews, J.L., see Wang, T.M., et al. *4*:193

Mautalen, C.A., Gonzalez, D., Casco, C., Fromm, G.A.:Healing of Osteitis Fibrosa Cystica After Partial Parathyroidectomy Despite Persistent Parathyroid Hyperfunction:A Case Report *4*:187

Mawrer, E.B., see Walker, D., *4*:361

Mazess, R.B., see Barden, H.S., et al. *4*:43

Mazza, A., Felluga, B., Curci, G.:A Histochemical Study of the Matrix of Long Bones of the Mouse Embryo Grown In Vitro *2*:65

McGuire, M.K.B., Russell, R.G.G., Murphy, G., Reynolds, J.J.:Effects of Diphosponates on Human Cells In Vitro:Inhibition of Production of Prostaglandins and Collagenase *4*:370

McIntosh, W.B., see Fogelman, I., et al. *4*:370

Mechanic, G.L., see Banes, A.J., *3*:81

Mechanic, G.L., see Boyde, A., et al. *1*:235

Meema, H.E., Rabinovich, S., Pierratos, A., Katirtzoglou, A., Murray, T.M., Orepoulos, D.G.:The Healing Effect of 1,25-Dihydroxyvitamin D_3 on Periosteal and Intracortical Resorption and Its Failure to Prevent Progression of Endosteal Resorption in Renal Osteodystrophy *2*:223

Mehls, O., see Kimmel, D., et al. *3*:191

Melsen, F., Mosekilde, L.:Dynamic Studies of Trabecular Bone Formation and Osteoid Maturation in Normal and Certain Pathological Conditions *1*:45

Melsen, F., see Emmertsen, K., et al. *4*:17

Melsen, F., see Kragstrup, J., et al. *3*:181, *4*:113, *4*:181, *4*:291

Melsen, F., see Mosekilde, L., *2*:77

Menanteau, J., Neuman, W.F., Neuman, M.W.:A Study of Bone Proteins Which Can Prevent Hydroxyapatite Formation *4*:157

Merret, A.L., see Compston, J.E., et al. *3*:165, *4*:362

Meunier, P., see Lambrey, G., et al. *4*:25

Meunier, P.J., see Alexandre, C., et al. *3*:309

Meunier, P.J., see Boyce, B.F., et al. *1*:35

Meunier, P.J., see Bressot, C., et al., *1*:303

Meunier, P.J., see Chapuy, M.C., et al. *2*:93, *4*:325

Meunier, P.J., see Delmas, P.D., et al. *4*:163

Meunier, P.J., see Goldsmith, R.S., et al. *1*:3

Meunier, P.J., see Reeve, J., et al. *3*:23

Meunier, P.J., see Sebert, J.L., et al. *2*:217

Michalik, J., see Dziedzic-Goclawska, A., et al. *2*:33

Middleton, J.F.S., see O'Connor, P., et al. *4*:365

Milford-Ward, A., see Russell, R.G.G., et al. *3*:255

Milhaud, G., Labat, M-L, Litwin, I., Moricard, Y., Moutier, R., Rimbaut, C., Buffee, D., Juster, M.:Osteopetro-rickets:A New Congenital Bone Disorder *3*:91

Miller, P., see Hruska, K.A., et al. *1*:39

Miller, S.C., Jee, W.S.S.:The Microvascular Bed of Fatty Bone Marrow in the Adult Beagle *2*:239

Miravet, L., see de Vernejoul, M.C., et al. *3*:175

Mirsky, N., see Silberman, M., et al. *4*:337

Miyahara, T., see Kawaguchi, Y., et al. *4*:333

Morey, E.R., see Wronski, T.J. *4*:69, *4*:347

Moricard, Y., see Milhaud, G., et al. *3*:91

Mosekilde, L., Melsen, F.:Dynamic Differences in Trabecular Bone Remodeling Between Patients After Jejuno-ileal Bypass for Obesity and Epileptic Patients Receiving Anticonvulsant Therapy *2*:77

Mosekilde, L., see Christensen, C.K., et al. *3*:17

Mosekilde, L., see Emmertsen, K., et al. *4*:17

Mosekilde, L., see Kragstrup, J., et al. *3*:181, *4*:113, *4*:181, *4*:291

Mosekilde, L., see Melsen, F. *4*:45

Moutier, R., see Dziedzic-Goclawska, A., et al. *2*:33

Moutier, R., see Milhaud, G., et al. *3*:91

Muhlrad, A., Stein, H., Bab, I.A., Sela, J.:Fine Structure and Enzymes of Matrix Vesicles in Osteosarcoma:Possible Occurrence of Contractile Proteins *1*:227

Muhlrad, A., see Deutsch, D., et al. *3*:209

Muhlrad, A., see Sela, et al. *1*:185

Muir, P., see Care, A.D., et al. *4*:371

Mundy, G., see Reeves, J., et al. *3*:135

Mundy, G.R., Eilon, G., Orr, W., Spiro, T.P., Yoneda, T.:Osteoclast Activating Factor:Its Role in Myeloma and Other Types of Hypercalcaemia of Malignancy *2*:173

Mundy, G.R., see Altman, A.J., et al. *1*:75

Muniz, O., see Howell, D.S., *1*:55

Murray, T.M., see Meema, H.E., et al. *2*:223

Murphy, G., see McGuire, M.K.B., et al. *4*:370

Neer, R.M., see Reeve, J., et al. *2*:233

Netelenbos, J.C., see Lips, P., et al. *4*:85

Neuman, M.W., see Menanteau, J., et al. *4*:157

Neuman, W.F., see Barrett, P.Q., et al. *1*:263

Neuman, W.F., see Menanteau, J., et al. *4*:157

Neuman, W.F., see Teitelbaum, A.P., et al. *2*:25

N'guyen, R.M., see Lambrey, G., et al. *4*:25

Nicholls, A.C., see Parry, R., et al. *4*:368

Nielsen, H.E., see Christensen, C.K., et al. *3*:17

Nielsen, H.E., see Emmertsen, K., et al. *4*:17

Nielsen, S., see Krolner, B. *4*:363

Nijweide, P.J., Kawilarang-de Haas, E.W.M., Wassenaar, A.M.:Alkaline Phosphatase and Calcification, Correlated or Not? *3*:61

Nikiforuk, G., Fraser, D.:Etiology of Enamel Hypoplasia and Interglobular Dentin:The Roles of Hypocalcemia and Hypophosphatemia *2*:17

Noorwali, A., Challa, A., Preston, C.J., Kanis, J.A., Russell, R.G.G.:Intracellular Inorganic Phosphate Levels in Normal Subjects and in Vitamin D-Resistant Rickets *4*:363

Norman, M.E., see Taylor, A., *4*:255

Norrdin, R.W., Shih, M.S.:Profiles of Cortical Remodeling Sites in Longitudinal Rib Sections of Beagles with Renal Failure and Parathyroid Hyperplasia *4*:353

Oates, K., see O'Connor, P., et al. *4*:365

O'Connor, P., Middleton, J.F.S., Oates, K., Gardner, D.L., Orford, C.R.:Freeze-replication:A Method for the Ultrastructural Examination of Fully Hydrated Natural Biologic Surfaces *4*:365

Oda, Y., see Kawaguchi, Y., et al. *4*:333

Ogura, Y., see Kawaguchi, Y., et al. *4*:333

Onions, D., see Allen, T.D., et al. *4*:372

Oreopoulos, D.G., see Meema, H.E., et al. *2*:223

Orford, C.R., see O'Connor, P., et al. *4*:365

O'Riordan, J.L.H., see Allgrove, J., et al. *4*:362

O'Riordan, J.L.H., see Compston, J.E., et al. *3*:165

Ornoy, A., see Atkin, I., *31*:199

Orr, W., see Mundy, G.R., et al. *2*:173

Ostrowski, K., see Dziedzic-Goclawska, A., et al. *2*:33

Owen, M.E., see Ashton, B.A., et al. *4*:368

Papadogeorgakis, N., see Robinson, P.B., et al. *4*:269

Parfitt, A.M.:The Coupling of Bone Formation to Bone Resorption:a Critical Analysis of the Concept and Its Relevance to the Pathogenesis of Osteoporosis (Editorial) *4*:1

Parfitt, A.M.: Equilibrium and Disequilibrim Hypercalcemia:New Light on an Old Concept *1*:279
Parfitt, A.M., see Flora, L., et al. *3*:289
Parry, R., Green, J.R., Harvey, J.J., Nicholls, A.C., Reeve, J., Tyrrell, D.A.J.: A Method for the Cultivation and Selection of Human Bone Cells *4*:368
Parsons, C., see Coombes, R.C., et al. *2*:199
Parsons, J.A., see Ashton, B.A., et al. *4*:368
Parsons, V., Emond, A., Dishe, F., Keenan, J., Darby, A.:Renal Failure Due to Tumor-induced Hypercalcaemia:Mechanisms and Treatment *2*:191
Parsons, V., Smith, J., Keenan, J., Lowes, J.:Tumor-induced Hypercalcemia Treated with APD *4*:363
Partridge, N.C., see Martin, T.J. *2*:167
Paterson, A., see Beard, D.J., et al. *4*:364
Paterson, A.D., see Douglas, D.L., et al. *3*:327
Paterson, A.D., see Russell, R.G.G., et al. *3*:255
Paton, S., see Cundy, T., et al. *1*:295
Pauwels, E.K.J., see Vellenga, C.J.L.R., et al. *4*:103
Peacock, M.:Hypercalcaemia and Calcium Homeostasis *2*:143
Peacock, M., see Selby, P.L., et al. *4*:371
Pennock, J., see Evans, I.M.A., et al. *2*:87
Perry, H.M., III, see Fallon, M.D., et al. *3*:171
Peters, J., see Loutit, J.F., et al. *3*:131
Petitfor, J.M., see Glorieux, F.H., et al. *3*:143
Phillips, M.E., see Eastwood, J.B., et al. *2*:83
Perratos, A., see Meema, H.E., et al. *2*:223
Pita, J.C., see Howell, D.S., et al. *1*:155
Plachot, J.J., Bailly du Bois, M., Halpern, S., Cournot-Witmer, G., Garabedian, M., Balsan, S.:In Vitro Action of 1,25-Dihydroxycholecalciferol on Matrix Organization and Mineral Distribution in Rabbit Growth Plate *4*:135
Posner, J., see Russell, R.G.G., et al. *3*:255
Posner, A.J., Betts, F., Blumenthal, N.C.:Properties of Nucleating Systems *1*:179
Posner, A.S., see Boskey, A.L., et al. *4*:151
Posner, A.S., see Lane, J.M., et al. *1*:319, *4*:61
Pouplard, A., see Rebel, A., et al. *3*:235
Powles, T.J., see Coombes, R.C., et al. *2*:199
Pradère, J., see Bouteiller, G., et al. *2*:123
Preston, C.J., see Noorwali, A., et al. *4*:363
Preston, C.J., see Russell, R.G.G., et al. *3*:255
Puel, P., see Bouteiller, G., et al. *2*:123

Quichaud, J., see Sebert, J.L., et al. *2*:217
Quint, P., see Höhling, H.J., et al. *1*:109

Rabinovich, S., see Meema, H.E., et al. *2*:223
Rader, J.I., Turner, R.T., Howard, G.A., Baylink, D.J.:Effect of Treatment with Parathyroid Extract on Bone Prameters and Metabolism of ^{3}H-25-Hydroxyvitamin D_3 in Hypocalcemic Thyroparathyroidectomized Rats *1*:313
Rader, J.I., see Liu, C-C, et al. *4*:201
Raisz, L.G., Simmons, H.A., Hansen, C.T.:Studies on Congenital Osteopetrosis in *tl* and *ia* rats Using Organ Culture *3*:117
Raisz, L.G., see Canalis, E., et al. *2*:99
Raisz, L.G., see Holtrop, M.E., et al. *3*:123
Raisz, L.G., see Kahn, A.J., *3*:77
Raisz, L.G., see King, G.J., et al. *1*:67
Rami, J., see Bouteiller, G., et al. *2*:123
Rasmussen, H.:Dedication to Philippe Bordier *1*:5
Rasmussen, H., Bordier, P.:Vitamin D and Bone *1*:7
Rasmussen, H., Bordier, P., Marie, P., Auquier, L., Erisinger, J.B., Kunts, D., Caulin, F., Argemi, B., Gueris, J., Julien, A.:Effect of Combined Therapy with Phosphate and Calcitonin on Bone Volume in Osteoporosis *2*:107
Reardon, G.E., see Canalis, E., et al. *2*:99
Rebel, A., Basle, M., Pouplard, A., Malkani, K., Filmon, R., Lepatezour, A.:Towards a Viral Etiology for Paget's Disease of Bone *3*:235
Rebel, A., see Basle, M.F., et al. *4*:305
Recker, R.R., see Schwartz, M.P. *4*:237
Reddi, A.H., see Eanes, E.D. *2*:3
Reeve, J., Arlot, M., Bernat, M., Charhon, S., Edouard, C., Slovik, D., Vismans, F.J.F.E., Meunier, P.J.:Calcium-47 Kinetic Measurements of Bone Turnover Compared to Bone Histomorphometry in Osteoporosis:The Influence of Human Parathyroid Fragment (hPTH 1-34) Therapy *3*:23
Reeve, J., Bijvoet, O.L.M., Neer, R.M., Slovik, D., Tellez, M., Vismans, F.J.F.E., Zanelli, G.D.:A Comparison Between the Balance Method and Radiotracer Methods for Measuring Calcium Absorption in Treated and Untreated Patients with Osteoporosis *2*:233
Reeve, J., see Hesp, R., et al. *4*:169
Reeve, J., see Parry, R., et al. *4*:368
Reeve, J., see Wootton, R., et al. *3*:263
Reeves, J., Arnaud, S., Gordon, S., Subryan, B., Block, M., Huffer, W., Arnaud, C., Mundy, G., Haussler, M.:The Pathogenesis of Infantile Malignant Osteopetrosis:Bone Mineral Metabolism and Complications in Five Infants *3*:135
Régis, H., see Bouteiller, G., et al. *2*:123
Renier, J.C., see Basle, M.F., et al. *4*:305
Revell, P., see Lager, R., et al. *4*:449
Reynolds, J.J., see McGuire, M.K.B., et al. *4*:370
Rezakovic, D., Jovanovic, V.:Correlation of Kinetics and Absorption of ^{47}Ca with Estrogen and Hormonal Ovarian Function in Postmenopause *4*:175
Richardson, C.A., see Hruska, K.A., et al. *1*:39
Riggan, L.J., see Boyan-Salyers, B.D., et al. *1*:143
Rimbaut, C., see Milhaud, G., et al. *3*:91
Ritchings, R.T., see Samuel, A.W., et al. *4*:362
Ritz, E., see Kimmel, D., et al. *3*:191
Ritz, E., see Krempien, B., *1*:55
Rizzoli, R., see Bonjour, J-P., et al. *1*:23
Robinson, C., Kirkham, J., Atkinson, P.J.:Nonamelogenin Components of the Developing Enamel Matrix *4*:372
Robinson, P.B., Harris, M., Harvey, W., Papadogeorgakis, N.:Reduced Bone Growth in Rats Treated with Anticonvulsant Drugs:A Type II Pseudothyroidism? *4*:269
Roelofs, J.M.M., see Visser, W.J., et al. *3*:187
Roos, B.A., see Ivey, J.L., et al. *3*:39
Roos, B.A., see Lambert, P.W., et al. *4*:7
Rose, P.G., see Barden, H.S., et al. *4*:43
Rosenberg, G.D., see Simmons, D.J., et al. *3*:51
Ross, A., see Care, A.D., et al. *4*:371
Ross, H.F., see Boyde, A., et al. *4*:372
Ross, R., see Care, A.D., et al. *4*:371
Rushton, S., see Lacey, E., et al. *4*:364
Russell, R.G.G., Beard, D.J., Cameron, E.C., Douglas, D.L., Forrest, A.R.W., Guilland-Cumming, D., Paterson, A.D., Poser, J., Preston, C.J., Milford-Ward, A., Woodhead, S., Kanis, J.A.:Biochemical Markers of Bone Turnover in Paget's Disease *3*:255
Russell, R.G.G., see Beard, D.J., et al. *4*:364
Russell, R.G.G., see Cundy, T., et al. *1*:295
Russell, R.G.G., see Douglas, D.L., et al. *3*:327
Russell, R.G.G., see Ibbotson, K.J., et al. *2*:177
Russell, R.G.G., see Kanis, J.A., *3*:217
Russell, R.G.G., see Kanis, J.A., et al. *2*:151, *3*:155, *3*:219
Russell, R.G.G., see McGuire, M.K.B., et al. *4*:370
Russell, R.G.G., see Noorwali, A., et al. *4*:363
Ryckewaert, A., see de Vernejoul, M.C., et al. *3*:175
Ryckewaert, A., see Sebert, J.L., et al. *2*:217

Sajdera, S.W., see Fortuna, R., et al. *1*:161
Salmon, M., Zanelli, J.M.:Cytochemical Responses in Rat Kidney After Intravenous Injection of Salmon Calcitonin *4*:364
Samuel, A.W., Checkley, D.R., Ritchings, R.T., Best, J.J.K.:Computed Tomography Bone Tumor Detection in the Rabbit *4*:362
Sany, J., see Bataille, R., *4*:39
Schneider, G.B., Cuenoud, M.L., Marks, S.C., Jr.:The Diagnosis and Cure of Neonatal Osteopetrosis:Experimental Evidence From Congenitally Osteopetrotic (*ia*) Rats *1*:335
Schneider, N., see Teitelbaum, A.P., et al. *2*:25
Schoenboerner, A., see Lager, R., et al. *4*:49
Schraer, H., see Gay, C.V., et al. *1*:105
Schwartz, M.P., Recker, R.R.:The Label Escape Error:Determination of the Active-bone-forming Surface in Histologic Sections of Bone Measured by Tetracycline Double Labels *4*:237
Sebert, J.L., Fournier, A., Gueris, J., Lambrey, G., de Fremont, J.F., Marie, P., Makdassi, R., Smadja, A., Marie, A., Kuntz, D., Ryckewaert, A., Quichaud, J., Meunier, P.J.:Limit by Hyperphosphatemia of the Usefulness of Vitamin D Metabolites (1α-Hydroxycholecalciferol and 25-Hydroxycholecalciferol) in the Treatment of Renal Osteodystrophy *2*:217
Sebert, J.L., see Lambrey, G., et al. *4*:25
Seideman, B., see Martino, L.J., *2*:261
Sela, J., Bab, I., Deol, M.S.:Patterns of Matrix Vesicle Calcification in Osteomalacia of Gyro Mice *4*:129
Sela, J., Bab, I.A., Muhlrad, A.:Ultrastructural and Biochemical Characterization of Extracellular Matrix Vesicles in Healing Alveolar Bone Sockets:Preliminary Indications for the Presence of Contractile Proteins *1*:185
Sela, J., see Deutsch, D., et al. *3*:209
Sela, J., see Muhlrad, A., et al. *1*:227
Selby, P.L., Peacock, M., Taylor, G.A., Storer, J.H.:The Role of Vitamin D in Calcium Excretion in Patients with Idiopathic Urinary Calcium Stone Disease *4*:371
Shapiro, I.M., Lee, N.H.:The Effect of Oxygen, Phosphoenolpyruvate and pH on the Release of Calcium from Chrondocyte Mitochondria *1*:173
Shellis, R.P.:A Possible Mechanism for the Formation of Calcospherites in Dentine *4*:366
Shen, F.H., see Ivey, J.L., et al. *3*:39
Shepard, N., see Glorieux, F.H., et al. *3*:143
Shih, M.S., see Norrdin, R.W., *4*:353
Silbermann, M., Lewinson, D., Toister, Z.:Early Cartilage Response to Systemic Glucocorticoid Administration:An Ultrastrucutral Study *2*:267
Silbermann, M., Mirsky, N., Levitan, S., Weisman, Y.:The Effect of 1,25-Dihydroxyvitamin D_3 on Cartilage Growth in Neonatal Mice *4*:337

Silbermann, M., Toister, Z., Lewinson, D.: Glucocorticoid-induced Changes in the Activity of Cartilage Alkaline Phosphatase 3:67
Silbermann, M., see Lewinson, D., 1:243, 4:143
Simmons, D.J., Teitelbaum, S.L., Rosenberg, G.D.: Altered Metabolic Rhythm of Rabbit Osteoblasts by Tetracycline 3:51
Simmons, D.J., Whiteside, L.A., Whitson, S.W.: Biorhythmic Profiles in the Rat Skeleton 2:49
Simmons, H.A., see Holtrop, M.E., et al. 3:123
Simmons, H.A., see Raisz, L.G., et al. 3:117
Singer, F.R., see Llach, F., et al. 2:11
Siris, E.S., Canfield, R.E., Jacobs, T.P., Stoddart, K.E., Spector, P.J.: Clinical and Biochemical Effects of EHDP in Paget's Disease of Bone Patterns of Response to Initial Treatment and to Long-term Therapy 3:301
Slatopolsky, E., see Hruska, K.A., et al. 1:39
Slovik, D., see Reeve, J., et al. 2:233, 3:23
Smadja, A., see Sebert, J.L., et al. 2:217
Smith, J., see Parsons, V., et al. 4:363
Smith, L.M., see Fogelman, I., et al. 4:362
Smith, M.L., Fogelman, I., Boyce, B.F., Boyle, I.T.: Skeletal Complications of Diphosphonate Therapy 4:373
Smith, R., see Cundy, T., et al. 1:295, 4:297
Sølling, H., see Emmertsen, K., et al. 4:17
Sørensen, O.H., see Christensen, C.K., et al. 3:17
Sørensen, O.H., see Emmertsen, K., et al. 4:17
Somers, S., see Wilkinson, R., et al. 4:364
Spector, P.J., see Siris, E.S., et al. 3:301
Spinks, T.J., see Hesp, R., et al. 4:169
Spiro, T.P., see Mundy, G.R., et al. 2:173
Stachowicz, W., see Dziedzic-Goclawska, A., et al. 2:33
Stein, H., see Huhlrad, A., et al. 1:227
Stevens, J.: Orthopaedic Aspects of Paget's Disease 3:271
Stevenson, J.C., MacIntyre, I., Townsend, P.R., Whitehead, M.I.: The Influence of Estrogen on Calcitonin Secretion in Postmenopausal Women 4:361
Stevenson, J.C., see Evand, I.M.A., et al. 2:87
Stoddart, K.E., see Siris, E.S., et al. 3:301
Storer, J.H., see Selby, P.L., et al. 4:371
Stover, S.L., see Finerman, G.A.M. 3:337
Subryan, B., see Reeves, J., et al. 3:135
Suda, T., see Kawaguchi, Y., et al. 4:333
Summers, F., see Boyan-Salyers, B.D., et al. 1:143
Sykes, A.R., see Care, A.D., et al. 4:371

Talmage, R.V., see Matthews, J.L., et al. 2:113
Taylor, A., Norman, M.E.: Interrelationship of Serum 25-Hydroxyvitamin D_3 and 1,25-Dihydroxyvitamin D in Juvenile Renal Osteodystrophy After Therapy with 25-Hydroxyvitamin D_3 4:255
Taylor, C.M., see Kanis, J.A., et al. 3:155
Taylor, G.A., see Selby, P.L., et al. 4:371
Teitelbaum, A.P., Schneider, N., Neuman, W.F.: On the Relation Between Peripheral Cleavage of Parathyroid Hormone and Its Biological Activity in Kidney 2:25
Teitelbaum, A.P., see Barrett, P.Q., et al. 1:263
Teitelbaum, S.L., Coccia, P.F., Brown, D.M., Kahn, A.J.: Malignant Osteopetrosis: A Disease of Abnormal Osteoclast Proliferation 3:99
Teitelbaum, S.L., see Fallon, M.D., et al. 3:171
Teitelbaum, S.L., see Hruska, K.A., et al. 1:39
Teitelbaum, S.L., see Simmons, D.J., et al. 3:51
Tellez, M., see Reeve, J., et al. 2:233
Tellez, M., see Wootton, R., et al. 3:263
Testa, N.G., see Allen, T.D., et al. 4:372
Te Velde, J., see Bijvoet, O.L.M., et al. 1:251
Tighe, J.R., see Vedi, S., et al. 4:231
Tinkler, S.M.B., Williams, D.M., Linder, J.E., Johnson, N.W.: The Importance of Blood Monocytes as a Source of Osteoclasts During Hormonally Stimulated Bone Resorption in the Mouse 4:365
Toister, Z., see Silbermann, M., et al. 2:267, 3:67
Tomlinson, S.: The Investigation of Hypercalcemia 2:161
Townsend, P.T., see Stevenson, J.C., et al. 4:361
Tomlinson, S., see Coulton, L.A., et al. 4:369
Tomlinson, S., see Walk, J.D., 4:361
Toyama, K., see Dziedzic-Goclawska, A., et al. 2:33
Travers, R., see Glorieux, F.H., et al. 3:143
Tukui, I., see Kawaguchi, Y., et al. 4:333
Turner, R.T., see Rader, J.I., et al. 1:313
Tyrrell, D.A.J., see Parry, R. et al. 4:368

van der Meer, C., see Lips, P., et al. 4:85
van der Sluys, V.J., see van Kesteren, R.G., et al. 4:31
van der Vijgh, W.J.F., see Lips, P., et al. 4:85
van Ginkel, F.C., see Lips, P., et al. 4:85
van Kesteren, R.G., Duursma, S.A., Visser, W.J., van der Sluys, V.J., Backer, D.O.: Fluoride in Serum and Bone During Treatment of Osteoporosis with Sodium Fluoride, Calcium and Vitamin D 4:31
van Schaik, C.L., see Lips, P., et al. 4:85
Vedi, S., Compston, J.E., Webb, A., Tighe, J.R.: Histomorphometric Analysis of Bone Biopsies from the Iliac Crest of Normal British Subjects 4:231
Vedi, S., see Compston, J.E., et al. 3:165
Vellenga, C.J.L.R., Pauwels, E.K.J., Bikvoet, O.L.M., Hosking, D.J., Frijlink, W.B.: Bone Scintigraphy in Paget's Disease Treated with Combined Calcitonin and Diphosphonate (EHDP) 4:103
Vellenga, C.J.L.R., see Bijvoet, O.L.M., et al. 1:251
Vermieden, J.P.W., see Lips, P., et al. 4:85
Vignon, E., see Delmas, P.D., et al. 4:163
Vigoni, F., see Bouteiller, G., et al. 2:123, 4:313
Villanueva, A.R., see Flora, L., et al. 3:289
Vismans, F.J.F.E., see Reeve, J., et al. 2:233, 3:23
Visser, W.J., Roelofs, J.M.M., Duursma, S.A.: Bone Density in the Iliac Crest 3:187
Visser, W.J., see van Kesteren, R.G., et al. 4:31
Vogel, J.J., Boyan-Salyers, B., Campbell, M.M.: Protein-phospholipid Interactions in Biologic Calcification 1:149
Vogel, J.J., see Boyan-Salyers, B.D., et al. 1:143
von Ahn, K., see Lambert, P.W., et al. 4:7

Walgate, J., see Haddad, J.G., et al. 3:43
Walk, J.D., Tomlinson, S.: Calmodulin: Intracellular Mediator of Calcium-dependent Processes 4:361
Walker, D., Adams, P.H., Mawrer, E.B.: Metabolism of Vitamin D in Patients with Nephrotic Syndrome 4:361
Wallach, S., see Kraszeski, J.L., et al. 3:9
Wang, T.M., Jee, W.S.S., Woodbury, L.A., Matthews, J.L.: Effects of Phytohemagglutinin-P (PHA-P) on Bone of the Growing Rat 4:193
Warman, M., Boskey, A.L.: Effect of High Levels of Corticosteroids on the Lipids of the Long Bones of the Mature Rabbit 4:319
Warner, G.P., see Wuthier, R.E., et al. 1:125
Warner, G.T., see Cundy, T., et al. 1:295
Wassenaar, A.M., see Nijweide, P.J., et al. 3:61
Webb, A., see Vedi, S., et al. 4:231
Weisman, Y., see Silbermann, M., et al. 4:337
Wergedal, J., see Evans, R.A., et al. 2:39
Wergedal, J., see Liu, C-C., et al. 1:269
Whitehead, M.I., see Stevenson, J.C., et al. 4:361
Whiteside, L.A., see Simmons, D.J., et al. 2:49
Whitson, S.W., see Simmons, D.J., et al. 2:49
Wilkinson, R., Fisken, R.A., Somers, S., Dowsett, C., Heath, D.A.: Hypercalcemia: Mechanisms and Predictive Tests 4:364
Williams, D.M., see Tinkler, S.M.B., et al. 4:365
Wisby, A., see Ali, S.Y., et al. 1:197
Woodbury, L.A., see Wang, T.M., et al. 4:193
Woodhead, J.S., see Beard, D.J., et al. 4:364
Woodhead, J.S., see Compston, J.E., et al. 3:165
Woodhead, S., see Russell, R.G.G., et al. 3:255
Wootton, R., Tellez, M., Green, J.R., Reeve, J.: Skeletal Blood Flow in Paget's Disease of Bone 3:263
Wronski, T.J., Morey, E.R.: Skeletal Abnormalities in Rats Induced by Simulated Weightlessness 4:69
Wronski, T.J., Morey, E.R.: Recovery of the Rat Skeleton from the Adverse Effects of Simulated Weightlessness 4:347
Wuthier, R.E., Linder, R.E., Warner, G.P., Gore, S.T., Borg, T.K.: Non-enzymatic Isolation of Matrix Vesicles: Characterization and Initial Studies on 45Ca and 32P-Orthophosphate Metabolism 1:125

Yamamoto, M., see Kawaguchi, Y., et al. 4:333
Yee, J.A., Jee, W.S.S.: The Effects of Ethane-1-Hydroxy-1, 1-Diphospohnate (EHDP) on the Proliferation and Differentiation of Stimulated Periodontal Ligament Fibroblasts 3:55
Yeh, J.K., Aloia, J.F.: The Relationship of Growth Hormone to 1,25-Dihyroxyvitamin D_3 in Intestinal Calcium Transport 3:47
Yeh, J.K., see Aloia, J.F., 2:251
Yoneda, T., see Mundy, G.R., et al. 2:173

Zanelli, G.D., see Reeve, J., et al. 2:233
Zanelli, see Salmon, M., 4:364

Compiled by Victoria Boyle